Vaccines and Global Health: The Week in Review 22 Feb 2014

Vaccines and Global Health: The Week in Review is a weekly digest — summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.
Email Summary: Vaccines and Global health : The Week in Review is published as a single email summary, scheduled for release each Saturday eveningbefore midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.
.
pdf version: A pdf of the current issues is available here: Vaccines and Global Health_The Week in Review_22 Feb 2014

Twitter: Readers can also follow developments on twitter: @vaxethicspolicy.
.
Links: We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.
.
Support: If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…
.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy
a program of the
– Division of Medical Ethics, NYU Medical School
– The Wistar Institute Vaccine Center
– Children’s Hospital of Philadelphia Vaccine Education Center
Associate Faculty, Division of Medical Ethics, NYU Medical School

WHO: 140,000 people to get cholera vaccine in South Sudan

WHO: 140,000 people to get cholera vaccine in South Sudan
News release – Excerpt
22 February 2014 | GENEVA – WHO is working with the South Sudan Government and partners to provide vaccines to protect nearly 140,000 people living in temporary camps in South Sudan against cholera.

The vaccines come from an emergency stockpile managed by WHO, the International Federation of the Red Cross and Red Crescent Societies (IFRC), Médecins Sans Frontières (MSF) and UNICEF. It is the first time the stockpile, created in 2013 by WHO, is being activated.

Although currently there is not a cholera outbreak, people displaced by the recent conflict and living in the camps are at risk due to poor sanitary conditions and overcrowding.

Starting today, 94,000 people will be vaccinated in the Minkaman camp, Awerial County, targeting displaced people and host communities, followed by vaccination campaigns in camps based in Juba, covering an additional 43 000 people.

Two doses of vaccine are required for an individual to be protected. The campaign begins with an initial round of vaccinations followed by – after a required 14 day interval – a second round of doses, which will complete the vaccination. For such a campaign to be effective, it is vital that a second dose is administered and this factor has led to the decision to begin with Minkaman, Awerial County, and Juba camps.

“Minkaman camp in Awerial County and Juba camp have been selected because of the relative stability of the situation and easier access in those places,” says Dr Abdinasir Abubakar, from WHO’s Disease Surveillance and Response team, in South Sudan. “We are also looking at other camps, and once the accessibility and security improves, we will expand the cholera vaccination campaigns into these areas. We will be reviewing the situation day by day.” …
http://www.who.int/mediacentre/news/releases/2014/cholera-vaccine-20140221/en/

Update: Polio this week – As of 19 February 2014

Update: Polio this week – As of 19 February 2014
Global Polio Eradication Initiative
Full report: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx

[Editor’s extract and bolded text]
:: In Pakistan, six new wild poliovirus type 1 (WPV1) and two new circulating vaccine-derived poliovirus type 2 (cVDPV2) cases are reported, all from the Federally Administered Tribal Areas (FATA) and Khyber Pakhtunkhwa (KP). Five of the cases are from North Waziristan and Peshawar, largely considered the ‘engine’ for polio transmission in the country.

Afghanistan
:: One new WPV1 case was reported in the past week from 2014. The total number of WPV1 cases remains 14 for 2013 and is now three for 2014. The most recent WPV1 case had onset of paralysis on 31 January 2014 from Kunar province, Eastern Region

Pakistan
:: Six new WPV1 cases were reported in the past week, four from North Waziristan, FATA and one from Bannu and Peshawar, respectively, in KP. The total number of cases for 2013 remains 93. The total number of cases in 2014 is now 15. The most recent case had onset of paralysis on 31 January (WPV1 from FR Bannu, FATA).
:: Two new cVDPV2 cases were reported in the past week. The total number of cVDPV2 cases for 2013 remains 45, and three for 2014. The most recent cVDPV2 case had onset of paralysis on 24 January (from FR Bannu, FATA).
:: North Waziristan is the district with the largest number of children being paralyzed by poliovirus in the world (both wild and cVDPV2). Immunization activities have been suspended by local leaders since June 2012. It is critical that children in all areas are vaccinated and protected from poliovirus. Immunizations in neighbouring high-risk areas are being intensified, to further boost population immunity levels in those areas and prevent further spread of this outbreak.
:: The densely populated Peshawar valley is considered to be the main ‘engine’ of poliovirus transmission, alongside North Waziristan, due to large-scale population movements through Peshawar from across this region, and into other areas of Pakistan. The quality of operations must be urgently improved in Peshawar, and immunizations resumed in North Waziristan.
:: However, at the same time, concerning trends have been noted in greater Karachi, Sindh and in Quetta, Balochistan. Environmental positives isolates from every major city of Punjab confirm widespread virus circulation

Horn of Africa
:: Two new WPV1 cases from Somalia were reported in the past week. Onset of paralysis for both cases was in June 2013. The cases were reported late due to a laboratory processing backlog. The total number of WPV1 cases in the Horn of Africa is now 215 (192 from Somalia, 14 from Kenya and nine from Ethiopia). The most recent WPV1 case in the region had onset of paralysis on 20 December 2013 (from Bari, Somalia).
:: Outbreak response across the Horn of Africa is continuing. Recommendations from the recently held Horn of Africa Technical Advisory Group (TAG), which convened two weeks ago in Nairobi, are now actively being incorporated into outbreak response planning. The TAG had underscored that the initial response to the outbreak was appropriate, however expressed grave concern that gaps in SIA quality and surveillance remained in key infected areas of the region. Consequently, the group concluded there is a serious risk of the outbreak continuing and of further spread both within and beyond countries of the Horn of Africa. The group recommended that infected countries should focus efforts on high-risk and infected areas, by conducting high-quality SIAs no more than four weeks apart.

Middle East
:: In Syria, one new WPV1 case was reported in the past week from Hasakeh governorate. The total number of laboratory-confirmed WPV1 cases is now 24. The most recent case had onset of paralysis on 17 December and was reported from Mara, Edleb governorate.
:: Additionally, there are 13 cases confirmed from contested areas but not yet reflected in official figures.

Editor’s Note: Please see post below for:
Editorials
The polio eradication end game: what it means for Europe
D Heymann 1,2, Q Ahmed3
Eurosurveillance
Volume 19, Issue 7, 20 February 2014

.
Gunmen kidnap six-member polio team in Pakistan
The Global Post/AFP via Agence France-Presse
February 17, 2014 14:12
The kidnapping is the latest setback to efforts to eradicate the disease in Pakistan. It followed a bombing on Sunday targeting a polio team in Peshawar which killed a policeman.
Excerpt
A Pakistani health worker administers a polio vaccination to a child during a polio immunization campaign in Peshawar on Feb. 2, 2014

Masked gunmen kidnapped a six-member polio vaccination team — a doctor, two local employees of the World Health Organization (WHO) and three guards — in northwest Pakistan on Monday, an official said.

Local administration official Niamat Ullah Khan said the team was seized some 190 miles southwest of Peshawar, in Ping village at the border of South Waziristan.

A local official of the WHO in Peshawar confirmed the incident…

http://www.globalpost.com/dispatch/news/regions/asia-pacific/pakistan/140217/gunmen-kidnap-six-member-polio-team-pakistan

.

  Rotary announced US$36 million in new grants supporting polio eradication. The grants include $6.8 million for Afghanistan, $7.7 million for Nigeria and $926,000 for Pakistan. Grant amounts “are based on requests from eradication initiative partners UNICEF and the World Health Organization, which work with the governments of polio-affected countries to plan and carry out immunization activities.” UNICEF will use a grant of $2.73 million to bolster vaccination activities throughout the Horn of Africa as part of an on-going response to an outbreak that began in 2013 and has now infected more than 200 children. The other countries where Rotary funds will be used to fight polio are Burkina Faso, $2.1 million; Cameroon, $3.4 million; Democratic Republic of Congo, $3.9 million; Niger, $2.3 million; Somalia, $1.3 million; South Sudan, $2.6 million; and Sudan, $1.2 million. WHO also received $934,000 to study the impact of introducing injectable, inactivated polio vaccine into the immunization program as part of the initiative’s endgame plan, as the goal of global eradication nears. Unrelated to this round of grants, Rotary released $500,000 in December 2013 as an emergency response to the polio outbreak in strife-torn Syria, which had not reported polio since 1999. Through Jan. 31, there were 23 confirmed cases in Syria since October 2013, all traceable to the polio strain circulating in Pakistan.
http://www.prnewswire.com/news-releases/rotary-releases-us359-million-to-fight-polio-in-africa-and-asia-246011091.html

Weekly Epidemiological Report (WER) for 21 February 2014

The Weekly Epidemiological Report (WER) for 21 February 2014, vol. 89, 8 (pp. 61–72) includes:
:: Preventive chemotherapy: planning, requesting medicines, and reporting
:: WHO Strategic Advisory Group of Experts (SAGE) on immunization: request for nominations
:: Monthly report on dracunculiasis cases, January– December 2013
http://www.who.int/entity/wer/2014/wer8908.pdf?ua=1

GAVI opens 2014 round of applications for new vaccines and health system strengthening support

GAVI Watch [to 22 February 2014]
http://www.gavialliance.org/library/news/press-releases/

GAVI has now opened its 2014 round of applications for new vaccines and health system strengthening support
New in 2014
Applications for both New Vaccine Support (NVS) and Health System Strengthening (HSS) will now be accepted through the same application and review timelines. The General Guidelines document offers an introduction to the principles, policies and processes that are applicable to all types of GAVI support.

Visit the updated section of the French website for all materials in French.

Countries are requested to submit an ‘Expression of Interest’ (EOI) as the first step in the application process. Submission of the EOI will be made mandatory starting with the September cut-off date for applications.

Country applications will be accepted on a rolling basis, so if a country misses a cut-off date, the application will be reviewed by the subsequent Independent Review Committee (IRC)

MMWR: Interim Estimates of 2013–14 Seasonal Influenza Vaccine Effectiveness — United States, February 2014

CDC/MMWR Watch [to 22 February 2014]
http://www.cdc.gov/mmwr/mmwr_wk.html

CDC Telebriefing: Update on Flu Activity and Vaccine Effectiveness Estimates – Transcript
Thursday, February 20, 2014, 12:00 PM
Telebriefing on articles that appear in today’s Morbidity and Mortality Weekly Report on Flu activity and 2013–14 Seasonal Influenza Vaccine Effectiveness.

MMWR Weekly
February 21, 2014 / Vol. 63 / No. 7
:: Interim Estimates of 2013–14 Seasonal Influenza Vaccine Effectiveness — United States, February 2014
February 21, 2014 / 63(07);137-142
Brendan Flannery, PhD1, Swathi N. Thaker, PhD1, Jessie Clippard, MPH1, Arnold S. Monto, MD2, Suzanne E. Ohmit, DrPH2, Richard K. Zimmerman, MD3, Mary Patricia Nowalk, PhD3, Manjusha Gaglani, MBBS4, Michael L. Jackson, PhD5, Lisa A. Jackson, MD5, Edward A. Belongia, MD6, Huong Q. McLean, PhD6, LaShondra Berman, MS1, Angie Foust, MA1, Wendy Sessions, MPH1, Sarah Spencer, PhD1, Alicia M. Fry, MD1

Excerpt
In the United States, annual vaccination against seasonal influenza is recommended for all persons aged ≥6 months (1). Each season since 2004–05, CDC has estimated the effectiveness of seasonal influenza vaccine to prevent influenza-associated, medically attended acute respiratory illness (ARI). This report uses data from 2,319 children and adults enrolled in the U.S. Influenza Vaccine Effectiveness (Flu VE) Network during December 2, 2013–January 23, 2014, to estimate an interim adjusted effectiveness of seasonal influenza vaccine for preventing laboratory-confirmed influenza virus infection associated with medically attended ARI. During this period, overall vaccine effectiveness (VE) (adjusted for study site, age, sex, race/ethnicity, self-rated health, and days from illness onset to enrollment) against influenza A and B virus infection associated with medically attended ARI was 61%. The influenza A (H1N1)pdm09 (pH1N1) virus that emerged to cause a pandemic in 2009 accounted for 98% of influenza viruses detected. VE was estimated to be 62% against pH1N1 virus infections and was similar across age groups. As of February 8, 2014, influenza activity remained elevated in the United States, the proportion of persons seeing their health-care provider for influenza-like illness was lower than in early January but remained above the national baseline, and activity still might be increasing in some parts of the country (2). CDC and the Advisory Committee on Immunization Practices routinely recommend that annual influenza vaccination efforts continue as long as influenza viruses are circulating (1). Persons aged ≥6 months who have not yet been vaccinated this season should be vaccinated. Antiviral medications are an important second line of defense to treat influenza illness and should be used as recommended (3) among suspected or confirmed influenza patients, regardless of patient vaccination status. Early antiviral treatment is recommended for persons with suspected influenza with severe or progressive illness (e.g., hospitalized persons) and those at high risk for complications from influenza, no matter how severe the illness.

:: Influenza-Associated Intensive-Care Unit Admissions and Deaths — California, September 29, 2013–January 18, 2014
:: Update: Influenza Activity — United States, September 29, 2013–February 8, 2014
:: Notes from the Field: Varicella-Associated Death of a Vaccinated Child with Leukemia — California, 2012

WHO Fact sheets: Immunization coverage :: Measles [Feb 2014]

WHO Fact sheet N°378: Immunization coverage:
Updated February 2014
Excerpt
Key facts
:: Immunization prevents illness, disability and death from vaccine-preventable diseases including diphtheria, measles, pertussis, pneumonia, polio, rotavirus diarrhoea, rubella and tetanus.
:: Global vaccination coverage is holding steady.
:: Immunization currently averts an estimated 2 to 3 million deaths every year.
:: But an estimated 22.6 million infants worldwide are still missing out on basic vaccines.

Overview
Immunization averts an estimated 2 to 3 million deaths every year from diphtheria, tetanus, pertussis (whooping cough), and measles. Global vaccination coverage—the proportion of the world’s children who receive recommended vaccines—has remained steady for the past few years. For example, the percentage of infants fully vaccinated against diphtheria-tetanus-pertussis (DTP3) has held steady at 83% for the last three years.

During 2012, about 110.6 million infants worldwide got three doses of DTP3 vaccine, protecting them against infectious diseases that can cause serious illness and disability or be fatal. By 2012, 131 countries had reached at least 90% coverage of DTP3…
http://www.who.int/mediacentre/factsheets/fs378/en/

WHO Fact sheet N°286: Measles
Updated February 2014
Excerpt
Key facts
:: Measles is one of the leading causes of death among young children even though a safe and cost-effective vaccine is available.
:: In 2012, there were 122 000 measles deaths globally – about 330 deaths every day or 14 deaths every hour.
:: Measles vaccination resulted in a 78% drop in measles deaths between 2000 and 2012 worldwide.
:: In 2012, about 84% of the world’s children received one dose of measles vaccine by their first birthday through routine health services – up from 72% in 2000.
:: Since 2000, more than 1 billion children in high risk countries were vaccinated against the disease through mass vaccination campaigns ― about 145 million of them in 2012…
http://www.who.int/mediacentre/factsheets/fs286/en/

Local discrepancies in measles vaccination opportunities: results of population-based surveys in Sub-Saharan Africa

BMC Public Health
(Accessed 22 February 2014)
http://www.biomedcentral.com/bmcpublichealth/content

Research article
Local discrepancies in measles vaccination opportunities: results of population-based surveys in Sub-Saharan Africa
Lise Grout, Nolwenn Conan, Aitana Juan Giner, Northan Hurtado, Florence Fermon, Alexandra N¿Goran, Emmanuel Grellety, Andrea Minetti, Klaudia Porten and Rebecca F Grais
Author Affiliations
BMC Public Health 2014, 14:193  doi:10.1186/1471-2458-14-193
Published: 21 February 2014
http://www.biomedcentral.com/1471-2458/14/193/abstract

Abstract (provisional)
Background
The World Health Organization recommends African children receive two doses of measles containing vaccine (MCV) through routine programs or supplemental immunization activities (SIA). Moreover, children have an additional opportunity to receive MCV through outbreak response immunization (ORI) mass campaigns in certain contexts. Here, we present the results of MCV coverage by dose estimated through surveys conducted after outbreak response in diverse settings in Sub-Saharan Africa. .

Methods
We included 24 household-based surveys conducted in six countries after a non-selective mass vaccination campaign. In the majority (22/24), the survey sample was selected using probability proportional to size cluster-based sampling. Others used Lot Quality Assurance Sampling.

Results
In total, data were collected on 60,895 children from 2005 to 2011. Routine coverage varied between countries (>95% in Malawi and Kirundo province (Burundi) while <35% in N’Djamena (Chad) in 2005), within a country and over time. SIA coverage was <75% in most settings. ORI coverage ranged from >95% in Malawi to 71.4% [95%CI: 68.9-73.8] in N’Djamena (Chad) in 2005.

In five sites, >5% of children remained unvaccinated after several opportunities. Conversely, in Malawi and DRC, over half of the children eligible for the last SIA received a third dose of MCV.

Conclusions
Control pre-elimination targets were still not reached, contributing to the occurrence of repeated measles outbreak in the Sub-Saharan African countries reported here. Although children receiving a dose of MCV through outbreak response benefit from the intervention, ensuring that programs effectively target hard to reach children remains the cornerstone of measles control.

Research article Systematic review on what works, what does not work and why of implementation of mobile health (mHealth) projects in Africa

BMC Public Health
(Accessed 22 February 2014)
http://www.biomedcentral.com/bmcpublichealth/content

Research article
Systematic review on what works, what does not work and why of implementation of mobile health (mHealth) projects in Africa
Clara B Aranda-Jan, Neo Mohutsiwa-Dibe and Svetla Loukanova
Author Affiliations
For all author emails, please log on.
BMC Public Health 2014, 14:188  doi:10.1186/1471-2458-14-188
Published: 21 February 2014
http://www.biomedcentral.com/1471-2458/14/188/abstract

Abstract (provisional)
Background
Access to mobile phone technology has rapidly expanded in developing countries. In Africa, mHealth is a relatively new concept and questions arise regarding reliability of the technology used for health outcomes. This review documents strengths, weaknesses, opportunities, and threats (SWOT) of mHealth projects in Africa.

Methods
A systematic review of peer-reviewed literature on mHealth projects in Africa, between 2003 and 2013, was carried out using PubMed and OvidSP. Data was synthesized using a SWOT analysis methodology. Results were grouped to assess specific aspects of project implementation in terms of sustainability and mid/long-term results, integration to the health system, management process, scale-up and replication, and legal issues, regulations and standards.

Results
Forty-four studies on mHealth projects in Africa were included and classified as: “patient follow-up and medication adherence” (n = 19), “staff training, support and motivation” (n = 2), “staff evaluation, monitoring and guidelines compliance” (n = 4), “drug supply-chain and stock management” (n = 2), “patient education and awareness” (n = 1), “disease surveillance and intervention monitoring” (n = 4), “data collection/transfer and reporting” (n = 10) and “overview of mHealth projects” (n = 2). In general, mHealth projects demonstrate positive health-related outcomes and their success is based on the accessibility, acceptance and low-cost of the technology, effective adaptation to local contexts, strong stakeholder collaboration, and government involvement. Threats such as dependency on funding, unclear healthcare system responsibilities, unreliable infrastructure and lack of evidence on cost-effectiveness challenge their implementation. mHealth projects can potentially be scaled-up to help tackle problems faced by healthcare systems like poor management of drug stocks, weak surveillance and reporting systems or lack of resources.

Conclusion
mHealth in Africa is an innovative approach to delivering health services. In this fast-growing technological field, research opportunities include assessing implications of scaling-up mHealth projects, evaluating cost-effectiveness and impacts on the overall health system.

The polio eradication end game: what it means for Europe

Eurosurveillance
Volume 19, Issue 7, 20 February 2014
http://www.eurosurveillance.org/Public/Articles/Archives.aspx?PublicationId=11678

Editorials
The polio eradication end game: what it means for Europe
D Heymann 1,2, Q Ahmed3
–       London School of Hygiene and Tropical Medicine, London, United Kingdom
–       Chatham House Centre on Global Health Security, London United Kingdom
–       State University of New York (SUNY) at Stony Brook, New York, United States

This edition of Eurosurveillance provides a series of articles related to polio that present a microcosm of some of the issues that have plagued polio eradication since the programme first began, and it also provides many of the solutions.

Had these and other issues been clearly understood in 1988 when the World Health Assembly passed the resolution that committed all countries to polio eradication by the year 2000, the decision to eradicate would have been more difficult. But fortunately, buoyed by the then recent success in the eradication of smallpox, active debate on whether to use inactivated or live polio vaccines, awareness that many countries had already interrupted polio transmission, and unawareness of the difficult eradication end game, the resolution was passed by consensus of the World Health Organization (WHO)’s member states [1]. Although progress towards eradication has been slower than anticipated in 1988, paralytic polio has decreased from an estimated 1,000 children per day during 1988, to approximately 400 during 2013. Today there remain only three countries with endemic polio, Afghanistan, Nigeria and Pakistan, and the recent risk assessment from the European Centre for Disease Prevention and Control (ECDC) reminds us that Europe must remain vigilant with strong surveillance and sustained laboratory capacity [2].

The series of polio articles in this edition begins with the article by Hindiyeh et al. [3] describing direct sewage testing for wild poliovirus antigen, using a multiplex quantitative reverse-transcription PCR (qRT-PCR) for rapid detection of the virus, directly on concentrated sewage samples. When compared to cell culture of the same sewage specimens, which is the initial process in the gold standard testing protocol for confirmation of polio, sensitivity and specificity of the multiplex system were shown to be high. Results were obtained in 24 to 48 hours, rather than the usual five to seven days required for the culture-based protocol.

The time from collection of a stool sample to analysis for polio virus in polio eradication programmes has often been weeks, not days, causing delays in response, more widespread transmission, and greater and more costly containment efforts. Recently though, times from specimen collection to outbreak control have decreased considerably by strengthening transport systems from the field to the laboratory, and modifying the testing protocol [4]. At the same time, there is active research and development of new testing algorithms that can provide more rapid results [5]. Hindiyeh et al. have concluded that their qRT-PCR system could be a promising application for testing of RNA extracted directly from processed stool samples from children with acute flaccid paralysis (AFP), and it remains to be seen whether further study will be conducted along these lines [3].

The article by Manor et al. [6] describes the discovery of a silent introduction of wild poliovirus, in the absence of detection of AFP in children (the standard surveillance methodology), by what they describe as an early warning system of sewage monitoring for poliovirus. They point out that this silent introduction occurred in a highly immune population in which inactivated polio vaccine (IPV) has been used exclusively since 2005, and that AFP surveillance alone had not detected this introduction and circulation. The authors suggest that there is a fundamental role for environmental surveillance in routine monitoring as an early warning system in polio-free countries, possibly more sensitive than surveillance for AFP. Shulman et al. [7] add greater perspective in their report on genetic sequencing of these wild polioviruses. It suggests that they were linked to strains that were circulating in South Asia and Egypt in 2012 and concludes that there had been one, or perhaps more than one, importation event.

Indeed, environmental monitoring in sewage has been used by many countries during the past decade, and it has identified wild poliovirus imported in 2007 to Switzerland from Chad, and in 2013 to Egypt from Pakistan [8,9]. Environmental surveillance has been a mainstay of polio eradication in several developing countries as well, for example in Egypt and India, and its wider role in the polio eradication end game continues to be assessed [10].
Van der Maas et al. [11] and Yakovenko et al. [12] discuss the importance of maintaining high polio immunity levels in order to prevent re-establishment of circulation of wild poliovirus, and the vulnerability of countries with lower than optimal population immunity in the general population or with pockets of low coverage such as those in certain religious and other groups. They clearly call attention to the fact that the circulation of wild poliovirus in one country is a threat to all others, and that vaccination coverage, using either IVP or oral polio vaccine (OPV), must be maintained until the circulation of all wild poliovirus has been interrupted. Yakovenko et al. also underscore the fact that adults are at risk from imported polio virus, having isolated wild poliovirus from adults with AFP in the Tajikistan outbreak [12].
A recent polio outbreak also provided a clear demonstration that adults are at risk of paralytic polio during outbreaks. Because adult populations in Namibia had not been vaccinated against polio in the period before independence, and had not developed immunity by exposure to poliovirus because of high quality water and sanitation systems, an importation of wild poliovirus led to an outbreak of paralytic polio in adults in 2006 [13].
Other issues that have been important to polio eradication such as circulating vaccine derived poliovirus (cVDPD) are not discussed in this series, although the ease with which the poliovirus recombines in nature was demonstrated by studies of viral sequences in the Tajikistan outbreak [12]. However, this omission from the series does not minimise the importance of cVDPV as a challenge to polio eradication that the end game will take into account [14]. The decision in Israel to reintroduce OPV after failure to interrupt transmission with IPV, foretells the complexity the end game will face in the event of a reintroduction after eradication has occurred. Outbreak containment strategies for all countries are actively being assessed for application during the post-eradication period [15].
Although solutions to most of the technical problems in polio eradication are either available or under development, risk communication and gaining trust in polio vaccination in the absence of paralytic disease remain a major challenge. This is clearly demonstrated by the experience described by Kaliner et al. [16] in developing trust and paving the way for the supplementary immunisation activities that reintroduce OPV several years after having switched to IPV in routine vaccination programmes.
The importance of trust and risk communication has likewise been clearly demonstrated in the past, when in 2003 polio vaccination was stopped in northern Nigeria because of false rumours, many of which were circulating on the world wide web, that the vaccine was being used in a plot by some Western nations to permanently sterilise young Muslim girls, and in some instances that it was associated with the introduction of AIDS [17]. Although there may have been other reasons than concern over vaccine safety, the governor of one northern state in Nigeria interrupted polio eradication activities, and other northern Nigerian states followed. Within months, polio had spread from Nigeria to neighbouring countries, to Saudi Arabia and Yemen, and from there on to Indonesia [18].

All of the countries affected were members of the Organization of the Islamic Conference who, at their October 2003 summit in Malaysia, adopted a resolution that endorsed and promoted stronger polio eradication activities [19]. Religious leaders became involved as well, and promoted polio vaccination through a series of fatwas and other declarations. Countries that had been free of polio, again had children paralysed by poliovirus, and increased their surveillance and conducted supplementary immunisation activities to prevent the virus from becoming endemic again. They were successful in containing wild poliovirus and interrupting its transmission, but at great financial cost to the countries and the polio partnership.

This series of articles on polio is a timely reminder that polio eradication has not yet been completed, and they confirm that eradication is technically feasible. But obstacles to polio eradication remain. Killings of polio workers in Pakistan and northern Nigeria have caused fear among polio workers, and pose a risk to the life of those who vaccinate door to door. These incidents have prompted a call for action from the Muslim world to counter opposition to the polio eradication programme recently published in The Lancet [20].

Civil unrest, such as that caused by the killing of polio workers, has occurred in the past, but was never targeted specifically at polio eradication. In Sudan in 2005, for example, the United Nations called for days of tranquillity so that polio and other vaccinations could continue [21].      But the solution to violence targeted at the global eradication of polio and at vaccination programmes in general, requires more than vaccine supplies, door-to-door vaccination, and meticulous surveillance. It requires collective ownership and solidarity by all countries, and it may need a prominent and accepted figure in all countries where opposition has been observed, to step forward as a leader and bring polio eradication to completion.

In the meantime, European countries must continue to maintain high levels of polio vaccination coverage, and sustained surveillance of AFP with laboratory support, in order to ensure that wild poliovirus, if imported, is rapidly detected and completely contained.

Miscellaneous
Note from the editors: Polio – good news and bad news
by Eurosurveillance editorial team

Research articles
Development and validation of a real time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assay for investigation of wild poliovirus type 1-South Asian (SOAS) strain reintroduced into Israel, 2013 to 2014
by MY Hindiyeh, J Moran-Gilad, Y Manor, D Ram, LM Shulman, D Sofer, E Mendelson

Molecular epidemiology of silent introduction and sustained transmission of wild poliovirus type 1, Israel, 2013
by LM Shulman, E Gavrilin, J Jorba, J Martin, CC Burns, Y Manor, J Moran-Gilad, D Sofer, MY Hindiyeh, R Gamzu, E Mendelson, I Grotto, for the Genotype – Phenotype Identification (GPI) group

Immunity against poliomyelitis in the Netherlands, assessed in 2006 to 2007: the importance of completing a vaccination series
by NA van der Maas, L Mollema, GA Berbers, DM van Rooijen, HG van der Avoort, MA Conyn-Van Spaendonck, HE de Melker, FR van der Klis

Surveillance and outbreak reports
Intensified environmental surveillance supporting the response to wild poliovirus type 1 silent circulation in Israel, 2013
by Y Manor, LM Shulman, E Kaliner, M Hindiyeh, D Ram, D Sofer, J Moran-Gilad, B Lev, I Grotto, R Gamzu, E Mendelson

The 2010 outbreak of poliomyelitis in Tajikistan: epidemiology and lessons learnt
by ML Yakovenko, AP Gmyl, OE Ivanova, TP Eremeeva, AP Ivanov, MA Prostova, OY Baykova, OV Isaeva, GY Lipskaya, AK Shakaryan, OM Kew, JM Deshpande, VI Agol

Perspectives
Silent reintroduction of wild-type poliovirus to Israel, 2013 – risk communication challenges in an argumentative atmosphere
by E Kaliner, J Moran-Gilad, I Grotto, E Somekh, E Kopel, M Gdalevich, E Shimron, Y Amikam, A Leventhal, B Lev, R Gamzu

Expanding the scope of medical mission volunteer groups to include a research component

Globalization and Health
[Accessed 22 February 2014]
http://www.globalizationandhealth.com/

Research
Expanding the scope of medical mission volunteer groups to include a research component
John Rovers, Michael Andreski, John Gitua, Abdoulaye Bagayoko and Jill DeVore
Author Affiliations
Globalization and Health 2014, 10:7  doi:10.1186/1744-8603-10-7
Published: 20 February 2014
http://www.globalizationandhealth.com/content/10/1/7/abstract

Abstract (provisional)
Background
Serving on volunteer groups undertaking medical mission trips is a common activity for health care professionals and students. Although volunteers hope such work will assist underserved populations, medical mission groups have been criticized for not providing sustainable health services that focus on underlying health problems. As members of a volunteer medical mission group, we performed a bed net indicator study in rural Mali. We undertook this project to demonstrate that volunteers are capable of undertaking small-scale research, the results of which offer locally relevant results useful for disease prevention programs. The results of such projects are potentially sustainable beyond the duration of a mission trip.

Methods
Volunteers with Medicine for Mali interviewed 108 households in Nana Kenieba, Mali during a routine two-week medical mission trip. Interviewees were asked structured questions about family demographics, use of insecticide treated bed nets the previous evening, as well as about benefits of net use and knowledge of malaria. Survey results were analyzed using logistic regression.

Results
We found that 43.7% of households had any family member sleep under a bed net the previous evening. Eighty seven percent of households owned at least one ITN and the average household owned 1.95 nets. The regression model showed that paying for a net was significantly correlated with its use, while low perceived mosquito density, obtaining the net from the public sector and more than four years of education in the male head of the household were negatively correlated with net use. These results differ from national Malian data and peer-reviewed studies of bed net use.

Conclusions
We completed a bed net study that provided results that were specific to our service area. Since these results were dissimilar to peer-reviewed literature and Malian national level data on bed net use, the results will be useful to develop locally specific teaching materials on malaria prevention. This preventive focus is potentially more sustainable than clinical services for malaria treatment. Although we were not able to demonstrate that our work is sustainable, our study shows that volunteer groups are capable of undertaking research that is relevant to their service area.

Regional variation in the allocation of development assistance for health

Globalization and Health
[Accessed 22 February 2014]
http://www.globalizationandhealth.com/

Short report
Regional variation in the allocation of development assistance for health
Michael Hanlon, Casey M Graves, Benjamin PC Brooks, Annie Haakenstad, Rouselle Lavado, Katherine Leach-Kemon and Joseph L Dieleman
Author Affiliations
Globalization and Health 2014, 10:8  doi:10.1186/1744-8603-10-8
Published: 20 February 2014
http://www.globalizationandhealth.com/content/10/1/8/abstract

Abstract (provisional)
Background
The Global Burden of Disease (GBD) 2010 Study has published disability-adjusted life year (DALY) data at both regional and country levels from 1990 to 2010. Concurrently, the Institute for Health Metrics and Evaluation (IHME) has published estimates of development assistance for health (DAH) at the country-disease level for this same period of time.

Findings
We use disease burden data from the GBD 2010 study and financing data from IHME to calculate ratios of DAH to DALYs across regions and diseases. We examine the magnitude of these ratios and how they have varied over time. We hypothesize that the variation in this ratio across regions would be relatively small. However, from 2006 to 2010, we find there was considerable variation in the levels of DAH per DALY across regions. For total funding, the relative standard deviation (standard deviation as a percentage of the mean) across regions was 50%. For DAH specific to HIV/AIDS, malaria and tuberculosis, the relative standard deviations were 50%, 200% and 60%, respectively. While these deviations are high, with the exception of malaria, they have decreased since the 1990s.

Conclusions
There are no evident explanations for so much variation in funding across regions, especially holding the purpose of the funding constant. This suggests donors’ allocation processes have not been particularly sensitive to disease burdens. To maximize health gains, donors should explicitly incorporate new disease burden data along with the relative costs and efficacy of interventions into their allocation process.

Meningococcal vaccine introduction in Mali through mass campaigns and its impact on the health system

Global Health: Science and Practice (GHSP)
February 2014 | Volume 2 | Issue 1
http://www.ghspjournal.org/content/current

Meningococcal vaccine introduction in Mali through mass campaigns and its impact on the health system
Sandra Mounier-Jacka, Helen Elizabeth Denise Burchetta, Ulla Kou Griffithsa, Mamadou Konateb, Kassibo Sira Diarrab
Author Affiliations
aLondon School of Hygiene & Tropical Medicine, London, UK
bIndependent Consultant, Bamako, Mali
The meningococcal A vaccine campaign led to major disruption of routine vaccination services and reduced other services, notably antenatal care.
http://www.ghspjournal.org/content/2/1/117.abstract

Abstract
Objective: To evaluate the impact of the meningococcal A (MenA) vaccine introduction in Mali through mass campaigns on the routine immunization program and the wider health system.

Methods: We used a mixed-methods case-study design, combining semi-structured interviews with 31 key informants, a survey among 18 health facilities, and analysis of routine health facility data on number of routine vaccinations and antenatal consultations before, during, and after the MenA vaccine campaign in December 2010. Survey and interview data were collected at the national level and in 2 regions in July and August 2011, with additional interviews in January 2012.

Findings: Many health system functions were not affected—either positively or negatively—by the MenA vaccine introduction. The majority of effects were felt on the immunization program. Benefits included strengthened communication and social mobilization, surveillance, and provider skills. Drawbacks included the interruption of routine vaccination services in the majority of health facilities surveyed (67%). The average daily number of children receiving routine vaccinations was 79% to 87% lower during the 10-day campaign period than during other periods of the month. Antenatal care consultations were also reduced during the campaign period by 10% to 15%. Key informants argued that, with an average of 14 campaigns per year, mass campaigns would have a substantial cumulative negative effect on routine health services. Many also argued that the MenA campaign missed potential opportunities for health systems strengthening because integration with other health services was lacking.

Conclusion: The MenA vaccine introduction interrupted routine vaccination and other health services. When introducing a new vaccine through a campaign, coverage of routine health services should be monitored alongside campaign vaccine coverage to highlight where and how long services are disrupted and to mitigate risks to routine services.

Understanding HPV Vaccine Uptake Among Cambodian American Girls

Journal of Community Health
Volume 39, Issue 1, February 2014
http://link.springer.com/journal/10900/39/1/page/1

Online First
Understanding HPV Vaccine Uptake Among Cambodian American Girls
Victoria M. Taylor, Nancy J. Burke, Linda K. Ko, Channdara Sos, Qi Liu, H. Hoai Do, Jocelyn Talbot, Yutaka Yasui, Roshan Bastani
http://link.springer.com/article/10.1007/s10900-014-9844-8

Abstract
Cervical cancer incidence rates vary substantially among racial/ethnic groups in the United States (US) with women of Southeast Asian descent having the highest rates. Up to 70 % of cervical cancers could be prevented by widespread use of the human papillomavirus (HPV) vaccine. However, there is a lack of information about HPV vaccine uptake among Southeast Asian girls in the US. We conducted a telephone survey of Cambodian women with daughters who were age-eligible for HPV vaccination. Survey items addressed HPV vaccination barriers, facilitators and uptake. Our study group included 86 Cambodian mothers who lived in the Seattle metropolitan area. The proportions of survey participants who reported their daughter had initiated and completed the HPV vaccine series were only 29 and 14 %, respectively. Higher levels of vaccine uptake were significantly associated with mothers having heard about the HPV vaccine from a health professional and having received a recent Pap test. Commonly cited barriers to HPV vaccination included lack of knowledge about the HPV vaccine, not having received a physician recommendation for HPV vaccination and thinking the HPV vaccine is unnecessary in the absence of health problems. Linguistically and culturally appropriate HPV educational programs should be developed and implemented in Cambodian American communities. These programs should aim to enhance understanding of disease prevention measures, increase knowledge about the HPV vaccine and empower women to ask their daughter’s doctors for HPV vaccination.

Update From the Advisory Committee on Immunization Practices

Journal of the Pediatric Infectious Diseases Society (JPIDS)
Volume 3 Issue 1 March 2014
http://jpids.oxfordjournals.org/content/current

Update From the Advisory Committee on Immunization Practices
Elizabeth P. Schlaudecker1, Mark H. Sawyer2 and David W. Kimberlin3
Author Affiliations
1Division of Infectious Diseases, Global Health Center, Cincinnati Children’s Hospital Medical Center, Ohio
2Division of Infectious Diseases, University of California San Diego, School of Medicine and Rady Children’s Hospital
3Division of Pediatric Infectious Diseases, University of Alabama at Birmingham

Excerpt
The Advisory Committee on Immunization Practices (ACIP) is composed of medical and public health experts and one community representative that meets 3 times a year to develop vaccine recommendations for the civilian population in the United States. The Advisory Committee on Immunization Practices recommendations become official recommendations of the Centers for Disease Control and Prevention (CDC) when adopted by the CDC Director and published in the Morbidity and Mortality Weekly Report (http://www.cdc.gov/vaccines/hcp/acip-recs/recs-by-date.html). Members of ACIP include people with expertise in vaccines, public health, and various aspects of medicine and preventive medicine (http://annals.org/article.aspx?articleid=744177

Members of the Pediatric Infectious Diseases Society frequently serve on this committee and on ACIP work groups, and our society serves as one of 31 ex officio organizations that participates as a nonvoting representative. The American Academy of Pediatrics (AAP) Committee on Infectious Diseases works closely with the ACIP to maximize harmonization between the CDC and the AAP. The ACIP last met at the CDC on October 23–24, 2013. During this meeting, there were 3 votes taken: meningococcal vaccine for high-risk infants; child/adolescent immunization schedule; and adult immunization schedule. Several other topics were discussed. All ACIP vaccine recommendations will have Grading of Recommendations, Assessment, Development and Evaluation methods applied (http://www.cdc.gov/vaccines/acip/recs/GRADE/table-refs.html

Automated Screening of Hospitalized Children for Influenza Vaccination

Journal of the Pediatric Infectious Diseases Society (JPIDS)
Volume 3 Issue 1 March 2014
http://jpids.oxfordjournals.org/content/current

Automated Screening of Hospitalized Children for Influenza Vaccination
Ari H. Pollack, Matthew P. Kronman, Chuan Zhou, and Danielle M. Zerr
J Ped Infect Dis (2014) 3 (1): 7-14 doi:10.1093/jpids/pit044
http://jpids.oxfordjournals.org/content/3/1/7.abstract

Abstract
Background
This study was designed to determine whether an automated hospital-based influenza vaccination screening program leveraging the electronic medical record (EMR) increases vaccination rates.

Methods
We performed a retrospective cohort study of all children ≥6 months old admitted to medical, surgical, rehabilitation, or psychiatry services during influenza seasons between 2003 and 2012 at a tertiary care pediatric hospital. We compared influenza vaccination rates before (preintervention phase) and after (intervention phase) the introduction of an automated EMR intervention that utilized a nursing-based electronic screening tool to determine eligibility for influenza vaccine and facilitated vaccine ordering without requiring involvement of a physician or other provider.

Results
Overall, 42 716 (72.8%) of the 58,648 subjects admitted during the study period met inclusion criteria. The intervention phase included 20,651 admissions, of which 11 194 (54.2%) were screened. Screening increased significantly over time in the intervention phase (19.8%–77.1%; P < .001). In-hospital influenza vaccination rates increased from a mean of 2.1% (n = 472) of all subjects preintervention phase to 8.0% (n = 1645) in the intervention phase (odds ratio = 6.8; 95% confidence interval, 6.14–7.47). Of the 11 194 screened subjects, 5505 (49.2%) were found to have already been vaccinated at the time of screening. The screening process identified 478 (4.3%) subjects who were unable to receive vaccine for medical reasons, and an additional 2865 (25.6%) whose caregiver refused the vaccine.

Conclusions
An automated, hospital-based influenza vaccination program integrated into the EMR can increase vaccinations of hospitalized patients and provide insight into the vaccination history and declination reasons for children not receiving the vaccine.

World View: WHO plans for neglected diseases are wrong

Nature   
Volume 506 Number 7488 pp265-402  20 February 2014
http://www.nature.com/nature/current_issue.html

Nature | Column: World View
WHO plans for neglected diseases are wrong
Research and development into diseases affecting the world’s poorest people will not benefit from the agency’s policy, warns Mary Moran.
19 February 2014
http://www.nature.com/news/who-plans-for-neglected-diseases-are-wrong-1.14739

Excerpt
After more than a decade of trying to find a way to fund research on diseases that affect the developing world, the World Health Organization (WHO) made a decisive move last month when it announced its first pilot projects. As Nature reported (see Nature 505, 142; 2014), the WHO hopes that these projects will break the stalemate over research on neglected conditions such as kala-azar, a deadly parasitic disease that afflicts hundreds of thousands of the world’s poorest people.

The WHO is taking giant strides, but they are in the wrong direction. The projects are based on flawed logic and will waste time and money. Worse, this initiative could actively damage existing projects to develop such medicines. The WHO pilot should be stopped.

I do not make these claims lightly. I was involved in the WHO analysis, drafting and recommendations, and know how difficult it has been.

The pilot projects are the culmination of a ten-year negotiation that aimed to achieve two goals: to make commercial medicines more affordable for the developing world, and to stimulate public (non-profit) development of medicines for neglected diseases…

Informed Consent, Comparative Effectiveness, and Learning Health Care :: Informed Consent for Pragmatic Trials — The Integrated Consent Model

New England Journal of Medicine
February 20, 2014  Vol. 370 No. 8
http://www.nejm.org/toc/nejm/medical-journal

Health Law, Ethics, and Human Rights
Informed Consent, Comparative Effectiveness, and Learning Health Care
Ruth R. Faden, Ph.D., M.P.H., Tom L. Beauchamp, Ph.D., and Nancy E. Kass, Sc.D.
N Engl J Med 2014; 370:766-768February 20, 2014DOI: 10.1056/NEJMhle1313674
http://www.nejm.org/doi/full/10.1056/NEJMhle1313674
The authors argue that in a learning health care system with ethically robust oversight policies, a streamlined consent process could replace formal written informed-consent procedures for many studies, and patient consent would not be required at all for some trials.

Health Law, Ethics, and Human Rights
Informed Consent for Pragmatic Trials — The Integrated Consent Model
Scott Y.H. Kim, M.D., Ph.D., and Franklin G. Miller, Ph.D.
N Engl J Med 2014; 370:769-772February 20, 2014DOI: 10.1056/NEJMhle1312508
http://www.nejm.org/doi/full/10.1056/NEJMhle1312508
The authors argue that informed consent is ethically necessary in pragmatic trials that randomly assign individual patients to treatments, even when treatment options are within the standard of care. They propose integration of a streamlined consent process into routine practice.

The Effects of Anti-Vaccine Conspiracy Theories on Vaccination Intentions

PLoS One
[Accessed 22 February 2014]
http://www.plosone.org/

Research Article
The Effects of Anti-Vaccine Conspiracy Theories on Vaccination Intentions
Daniel Jolley mail, Karen M. Douglas mail
Published: February 20, 2014
DOI: 10.1371/journal.pone.0089177
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0089177

Abstract
The current studies investigated the potential impact of anti-vaccine conspiracy beliefs, and exposure to anti-vaccine conspiracy theories, on vaccination intentions. In Study 1, British parents completed a questionnaire measuring beliefs in anti-vaccine conspiracy theories and the likelihood that they would have a fictitious child vaccinated. Results revealed a significant negative relationship between anti-vaccine conspiracy beliefs and vaccination intentions. This effect was mediated by the perceived dangers of vaccines, and feelings of powerlessness, disillusionment and mistrust in authorities. In Study 2, participants were exposed to information that either supported or refuted anti-vaccine conspiracy theories, or a control condition. Results revealed that participants who had been exposed to material supporting anti-vaccine conspiracy theories showed less intention to vaccinate than those in the anti-conspiracy condition or controls. This effect was mediated by the same variables as in Study 1. These findings point to the potentially detrimental consequences of anti-vaccine conspiracy theories, and highlight their potential role in shaping health-related behaviors.

Distance to health services affects local-level vaccine efficacy for pneumococcal conjugate vaccine (PCV) among rural Filipino children

PNAS – Proceedings of the National Academy of Sciences of the United States
of America

http://www.pnas.org/content/early/
(Accessed 22 February 2014)

Distance to health services affects local-level vaccine efficacy for pneumococcal conjugate vaccine (PCV) among rural Filipino children
Elisabeth Dowling Roota,1, Marilla Lucerob, Hanna Nohynekc, Peter Anthamattend, Deborah S. K. Thomasd, Veronica Tallob, Antti Tanskanenc,e, Beatriz P. Quiambaob, Taneli Puumalainenf,
Socorro P. Lupisanb, Petri Ruutug, Erma Ladesmab, Gail M. Williamsh, Ian Rileyh, and Eric A. F. Simõesi
Author Affiliations
Edited by Burton H. Singer, University of Florida, Gainesville, FL, and approved January 21, 2014 (received for review July 22, 2013)
http://www.pnas.org/content/early/2014/02/13/1313748111.short

Significance
Although pneumococcal conjugate vaccines (PCVs) are widely available in industrialized nations, the cost of these vaccines and the strategy of universal vaccination of infants, as endorsed by the World Health Organization, are daunting obstacles to the adoption of these vaccines in developing countries. Using spatial epidemiological methods to examine the spatial variation in vaccine efficacy (VE) in an 11-valent PCV trial in Bohol, Philippines, we suggest an alternative strategy to universal vaccination. Our main finding suggests that areas with poor access to healthcare have the highest VE. An alternative vaccination strategy could target vaccination to areas where children are most likely to benefit, rather than focus on nationwide immunization.

Abstract
Pneumococcal conjugate vaccines (PCVs) have demonstrated efficacy against childhood pneumococcal disease in several regions globally. We demonstrate how spatial epidemiological analysis of a PCV trial can assist in developing vaccination strategies that target specific geographic subpopulations at greater risk for pneumococcal pneumonia. We conducted a secondary analysis of a randomized, placebo-controlled, double-blind vaccine trial that examined the efficacy of an 11-valent PCV among children less than 2 y of age in Bohol, Philippines. Trial data were linked to the residential location of each participant using a geographic information system. We use spatial interpolation methods to create smoothed surface maps of vaccination rates and local-level vaccine efficacy across the study area. We then measure the relationship between distance to the main study hospital and local-level vaccine efficacy, controlling for ecological factors, using spatial autoregressive models with spatial autoregressive disturbances. We find a significant amount of spatial variation in vaccination rates across the study area. For the primary study endpoint vaccine efficacy increased with distance from the main study hospital from −14% for children living less than 1.5 km from Bohol Regional Hospital (BRH) to 55% for children living greater than 8.5 km from BRH. Spatial regression models indicated that after adjustment for ecological factors, distance to the main study hospital was positively related to vaccine efficacy, increasing at a rate of 4.5% per kilometer distance. Because areas with poor access to care have significantly higher VE, targeted vaccination of children in these areas might allow for a more effective implementation of global programs.

Challenges of health measurement in studies of health disparities

Social Science & Medicine
Volume 106,   In Progress   (April 2014)
http://www.sciencedirect.com/science/journal/02779536/106

Challenges of health measurement in studies of health disparities
Review Article
Pages 143-150
Sarah A. Burgard, Patricia V. Chen
Abstract
Health disparities are increasingly studied in and across a growing array of societies. While novel contexts and comparisons are a promising development, this commentary highlights four challenges to finding appropriate and adequate health measures when making comparisons across groups within a society or across distinctive societies. These challenges affect the accuracy with which we characterize the degree of inequality, limiting possibilities for effectively targeting resources to improve health and reduce disparities. First, comparisons may be challenged by different distributions of disease and second, by variation in the availability and quality of vital events and census data often used to measure health. Third, the comparability of self-reported information about specific health conditions may vary across social groups or societies because of diagnosis bias or diagnosis avoidance. Fourth, self-reported overall health measures or measures of specific symptoms may not be comparable across groups if they use different reference groups or interpret questions or concepts differently. We explain specific issues that make up each type of challenge and show how they may lead to underestimates or inflation of estimated health disparities. We also discuss approaches that have been used to address them in prior research, note where further innovation is needed to solve lingering problems, and make recommendations for improving future research. Many of our examples are drawn from South Africa or the United States, societies characterized by substantial socioeconomic inequality across ethnic groups and wide disparities in many health outcomes, but the issues explored throughout apply to a wide variety of contexts and inquiries.

From Google Scholar+ [to 22 February 2014]

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

The Influence of Deductible Health Plans on Receipt of the Human Papillomavirus Vaccine Series
Douglas W. Roblin, Ph.D.a, b, Debra P. Ritzwoller, Ph.D.c, Daniel I. Rees, Ph.D.d, Nikki M. Carroll, M.S.c, Anping Chang, M.S.a, Matthew F. Daley, M.D., M.P.H.c
Journal of Adolescent Health
Volume 54, Issue 3, March 2014, Pages 275–281
http://www.sciencedirect.com/science/article/pii/S1054139X13007957
Abstract
Purpose
To evaluate whether enrollment in deductible health plans (DHP) with higher patient cost-sharing requirements than traditional health maintenance organization plans (HMP) decreased initiation and completion of the human papillomavirus (HPV) vaccine series recommended for prevention of cervical cancer.
Methods
This was a retrospective observational study of 9- to 26-year-old females at Kaiser Permanente Georgia and Kaiser Permanente Colorado who were HPV vaccine naive at time of enrollment in a self-pay DHP or HMP in 2007. Estimates of rates of initiation and completion of the HPV vaccine series from plan enrollment in 2007 through December 2009 were obtained using Cox proportional hazards regressions (accounting for censoring) on samples matched on the propensity to enroll in a DHP versus HMP.
Results
Initiation of the HPV vaccine series was 22.2% and 24.4% in the DHP and HMP groups, respectively, at Kaiser Permanente Georgia; completion was 12.3% and 14.4% in the DHP and HMP groups, respectively. Human papillomavirus vaccine series initiation was higher at Kaiser Permanente Colorado, but completion was lower. In the Cox proportional hazards regressions, rates of initiation and completion of the HPV vaccine series did not differ significantly (p ≤ .05) by plan type (DHP vs. HMP) at both sites. The primary care visit rate included in these regressions had a significant, positive association with initiation and completion of the HPV vaccine series.
Conclusions
Enrollment in a DHP versus an HMP did not directly affect initiation or completion of the HPV vaccine series among age-eligible females. Independent of plan type, more frequent primary care visits increased initiation and completion rates.

Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries
Dr Kalipso Chalkidou PhD a, Patricio Marquez MD b, Preet K Dhillon PhD c, Yot Teerawattananon MD d, Thunyarat Anothaisintawee PhD e, Prof Carlos Augusto Grabois Gadelha PhD f, Prof Richard Sullivan MD g
The Lancet Oncology, Early Online Publication, 14 February 2014
doi:10.1016/S1470-2045(13)70547-3
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2813%2970547-3/fulltext
Summary
Evidence-informed frameworks for cost-effective cancer prevention and management are essential for delivering equitable outcomes and tackling the growing burden of cancer in all resource settings. Evidence can help address the demand side pressures (ie, pressures exerted by people who need care) faced by economies with high, middle, and low incomes, particularly in the context of transitioning towards (or sustaining) universal health-care coverage. Strong systems, as opposed to technology-based solutions, can drive the development and implementation of evidence-informed frameworks for prevention and management of cancer in an equitable and affordable way. For this to succeed, different stakeholders—including national governments, global donors, the commercial sector, and service delivery institutions—must work together to address the growing burden of cancer across economies of low, middle, and high income.

The influence of social norms on the dynamics of vaccinating behaviour for paediatric infectious diseases
Tamer Oraby1, Vivek Thampi1 and Chris T. Bauch1,2
1Department of Mathematics and Statistics, University of Guelph, Guelph, Ontario, Canada
2Department of Applied Mathematics, University of Waterloo, Waterloo, Ontario, Canada
Proceedings of the Royal Society B
April 2014 vol. 281 no. 1780 20133172
Abstract
Mathematical models that couple disease dynamics and vaccinating behaviour often assume that the incentive to vaccinate disappears if disease prevalence is zero. Hence, they predict that vaccine refusal should be the rule, and elimination should be difficult or impossible. In reality, countries with non-mandatory vaccination policies have usually been able to maintain elimination or very low incidence of paediatric infectious diseases for long periods of time. Here, we show that including injunctive social norms can reconcile such behaviour-incidence models to observations. Adding social norms to a coupled behaviour-incidence model enables the model to better explain pertussis vaccine uptake and disease dynamics in the UK from 1967 to 2010, in both the vaccine-scare years and the years of high vaccine coverage. The model also illustrates how a vaccine scare can perpetuate suboptimal vaccine coverage long after perceived risk has returned to baseline, pre-vaccine-scare levels. However, at other model parameter values, social norms can perpetuate depressed vaccine coverage during a vaccine scare well beyond the time when the population’s baseline vaccine risk perception returns to pre-scare levels. Social norms can strongly suppress vaccine uptake despite frequent outbreaks, as observed in some small communities. Significant portions of the parameter space also exhibit bistability, meaning long-term outcomes depend on the initial conditions. Depending on the context, social norms can either support or hinder immunization goals.

Vaccines and Global Health: The Week in Review 15 Feb 2014

Vaccines and Global Health: The Week in Review is a weekly digest — summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated “29 June 2013″
.
Email Summary: Vaccines and Global health : The Week in Review is published as a single email summary, scheduled for release each Saturday eveningbefore midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.
.
pdf version: A pdf of the current issues is available here: Vaccines and Global Health_The Week in Review_15 Feb 2014

Twitter: Readers can also follow developments on twitter: @vaxethicspolicy.
.
Links: We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.
.
Support: If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…
.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy
a program of the
– Division of Medical Ethics, NYU Medical School
– The Wistar Institute Vaccine Center
– Children’s Hospital of Philadelphia Vaccine Education Center
Associate Faculty, Division of Medical Ethics, NYU Medical School

Global Health Security Agenda launched — 30 partner countries, agencies

The United States joined 26 countries, the WHO, the Food and Agriculture Organization (FAO), and the World Organization for Animal Health (OIE) in committing to the goals of the Global Health Security Agenda “to accelerate progress toward a world safe and secure from the threat of infectious disease.” Over the next five years the United States plans to work with at least 30 partner countries (containing at least 4 billion people) “to prevent, detect and effectively respond to infectious disease threats, whether naturally occurring or caused by accidental or intentional releases of dangerous pathogens.” Later this year, the White House will host an event bringing together nations who are committed to protecting the world from infectious disease threats to review progress and chart the way forward on building a global system for preventing, detecting, and responding to such threats. CDC Director Dr. Tom Frieden commented, “The United States and the world can and must do more to prevent, detect, and respond to outbreaks as early and as effectively as possible. CDC conducted two global health security demonstration projects last year in partnership with Vietnam and Uganda to strengthen laboratory systems, develop strong public health emergency operations centers, and create real-time data sharing in health emergencies.  CDC is committed to replicate the successes in these two projects in ten additional countries this year.”

U.S. government departments including HHS, DoS, USDA, and DoD “will work closely with global partners to build countries’ global health security capacities in areas such as surveillance, detection and response in order to slow the spread of antimicrobial resistance, establish national biosecurity systems, reduce zoonotic disease transmission, increase routine immunization, establish and strengthen national infectious disease surveillance and laboratory systems, and develop public health electronic reporting systems and emergency operations centers.” Countries joining the United States to meet the Global Health Security goals at today’s launch were Argentina, Australia, Canada, Chile, China, Ethiopia, Finland, France, Georgia, Germany, India, Indonesia, Italy, Japan, Kazakhstan, Mexico, Netherlands, Norway, Republic of Korea, Russian Federation, Saudi Arabia, South Africa, Turkey, Uganda, United Kingdom, and, Vietnam.

www.globalhealth.gov/global-health-topics/global-health-security/index.html.
http://www.hhs.gov/news/press/2014pres/02/20140213a.html

UNICEF, Government of Guinea, NGO partners vaccinate over 1.7 million children in Guinea

UNICEF said that together with the Government of Guinea and other NGO partners, it vaccinating over 1.7 million children in Guinea amid a continuing measles outbreak. Yesterday, the Ministry of Health announced that there are over 1,300 new suspected cases and five child deaths since the beginning of 2014. UNICEF Representative in Guinea Dr. Mohamed Ag Ayoya commented, “In Guinea, where three out of five children are not fully vaccinated, measles can have a devastating impact as it spreads quickly and kills children. UNICEF has worked quickly to provide expertise, vaccines and other materials and stands ready to support the Government in any way we can.”
http://www.unicef.org/media/media_71996.html

WHO: Medical supplies air-delivered to north-east Syria

WHO: Humanitarian Health Action
http://www.who.int/hac/en/index.html

Medical supplies air-delivered to north-east Syria
WHO started to deliver medicines, vaccine and medical supplies to north-east Syria this week by chartered flights from the capital Damasacus. WHO is providing medical supplies for more than 335 000 beneficiaries, including medicines for chronic and infectious diseases, skin diseases, as well as medical supplies needed to treat patients with injuries.
Read the story on medical supplies to north-east Syria

Speech: WHO Director-General celebrates polio-free India

Speech: WHO Director-General celebrates polio-free India
Dr Margaret Chan, Director-General of the World Health Organization
Address at the “India celebrates triumph over polio” event;  New Delhi, India
11 February 2014

Excerpt
…India has shown the world that there is no such thing as impossible. This is likely the greatest lesson, and the greatest inspiration for the rest of the world.

India’s leadership in polio eradication is widely appreciated and warmly welcomed, especially among the 194 Member States of WHO. The country has shared its experiences, best practices, lessons learned, and expert staff with the remaining endemic countries.

The defeat of polio in India paves the way for certification of the entire South-East Asia region as polio-free, possibly at the end of March. When this happens, nearly 80% of the world’s population will be living in countries that are certified polio-free.

The polio-free status of every country remains under threat as long as poliovirus is still circulating anywhere in the world. We still have some way to go. But India provides the decisive proof that eradication is feasible, technically and operationally.

India is fully aware of the need to safeguard its magnificent achievement. Immunization against polio remains high, and emergency preparedness and response plans are in place to respond urgently to any importations.

India will continue its role as a global leader as the Polio Endgame is implemented, including through the introduction of inactivated polio vaccine and the stepwise phasing out of oral polio vaccine.

Right now, the country is using the legacy of its polio success to intensify routine immunization, with a special emphasis on reaching underserved and marginalized populations.    The elimination of measles will likely be the next permanent improvement for the health of India’s people.

The 13 January news that India had now gone 3 years without a polio case made headlines around the world. This is a monumental achievement that fully deserves today’s celebration.
Full text of speech: http://www.who.int/dg/speeches/2014/india-polio-free/en/index.html

[India] Vaccination must for visitors from polio-hit nations

[India] Vaccination must for visitors from polio-hit nations
The Hindu | 9 February 2014

From March 1, polio vaccination will be mandatory for all international travellers coming to India from polio-infected countries.

The Health Ministry has also made OPV (oral polio vaccine) compulsory for those travelling from India to polio-endemic countries and countries with poliovirus circulation to prevent virus importation.

The polio-endemic countries are Afghanistan, Nigeria and Pakistan. Countries with poliovirus circulation are Ethiopia, Kenya, Somalia and Syria.

OPV vaccination certificates, valid for one year, will be issued by the government.

Resident nationals of the seven infected countries are required to receive an OPV dose, regardless of age and vaccination status, at least four weeks prior to departure for India. The vaccination certificate will have to be produced while applying for visa and during travel in India.

However, OPV is not mandatory for foreign nationals residing in the seven infected countries or India before their travel.

Travellers can contact local health authorities in their countries for vaccination and certificates.

Travellers from India to countries with poliovirus transmission should receive a dose of OPV at least four weeks prior to departure.

Each district has designated at least one centre where OPV vaccination will be given and certificate issued. The District Immunisation Officer is the designated official for issue of certificates.

GPEI Update: Polio this week – As of 12 February 2014

Update: Polio this week – As of 12 February 2014
Global Polio Eradication Initiative
Full report: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx

[Editor’s extract and bolded text]
:: Celebrating 3 years polio-free in India: on 11 February, dignitaries from around the world came together at a celebratory event in Delhi. The President of India, Shri Pranab Mukherjee, was joined in the celebrations by Prime Minister Dr Manmohan Singh, Union Health and Family Welfare Minister Ghulam Nabi Azad, Chairperson of the National Advisory Council Sonia Gandhi, Leader of the Opposition Shushma Swaraj, WHO Director-General Dr Margaret Chan, Rotary International President Ron D Burton and other high-level representatives. The Regional Certification Commission (RCC) for the Southeast Asia Region is expected to convene at end-March and review data from the entire Region, to determine if it will be officially certified as polio-free.
:: In Afghanistan, an immunization response is ongoing to last week’s reported case in Kabul. It was the first case in the province since 2002, and is linked to transmission in neighbouring Pakistan. Afghanistan continues to make strong progress towards polio eradication. This latest case in Kabul underscores the ongoing risk polio continues to pose to children everywhere.

Afghanistan
:: One new wild poliovirus type 1 (WPV1) case was reported in the past week. The total number of WPV1 cases remains 14 for 2013, but is now two for 2014. The most recent WPV1 case had onset of paralysis on 15 January 2014 from Badakhstan province, Northern Region.

Nigeria
:: One new cVDPV2 case was reported in the past week. The total number of cVDPV2 cases for 2013 is now 4. The most recent cVDPV case had onset of paralysis on 24 December (from Maiduguri, Borno).
:: An appropriate response to this most recent cVDPV2 case in Borno is now being planned. The cVDPV2 case is linked to previous transmission in Chad from 2013.
:: The persisting transmission of two separate strains of cVDPV2 (from AFP cases and from the environment) in northern Nigeria and in north-West Pakistan is of concern to the GPEI since the ‘withdrawal’ of type 2 OPV vaccine (the ‘tOPV to bOPV switch’), planned for early 2016, will not be possible unless all persistent cVDPV2 transmission has been stopped.

Pakistan
:: Two new WPV1 cases were reported in the past week, both from North Waziristan in FATA (with onset of paralysis on 17 and 25 January 2014). The total number of cases for 2013 remains 93. The total number of cases in 2014 is now nine. The most recent case had onset of paralysis on 25 January 2014 (WPV1 from North Waziristan).
:: North Waziristan is the district with the largest number of children being paralyzed by poliovirus in the world (both wild- and VDPV2). Immunization activities have been suspended by local leaders since June 2012. It is critical that children in all areas are vaccinated and protected from poliovirus. Immunizations in neighbouring high-risk areas are being intensified, to further boost population immunity levels in those areas and prevent further spread of this outbreak.
:: The densely populated Peshawar valley is considered to be the main ‘engine’ of poliovirus transmission, alongside North Waziristan, due to large-scale population movements through Peshawar from across this region, and into other areas of Pakistan. The quality of operations must be urgently improved in Peshawar, and immunizations resumed in North Waziristan.
However, at the same time, concerning trends have been noted in greater Karachi, Sindh and in Quetta, Balochistan. Environmental positives isolates from every major city of Punjab confirm widespread virus circulation.
:: In Quetta, genetic sequencing of a positive environmental sample collected on 28 December 2013 indicates that it is linked to virus last detected in Afghanistan in July 2012, suggesting undetected circulation. Subnational analyses of surveillance sensitivity and immunity profiles are ongoing in both countries to ascertain more clarity. This further underscores the risk ongoing transmission anywhere, including low-level transmission, poses to the polio eradication efforts of both countries.

Horn of Africa
:: The Horn of Africa Technical Advisory Group (TAG) convened last week in Nairobi, Kenya, to evaluate impact of current outbreak response activities. The TAG underscored that the initial response to the outbreak was appropriate, however expressed grave concern that gaps in SIA quality and surveillance remained in key infected areas of the region. Consequently, the group concluded there is a serious risk of the outbreak continuing and of further spread both within and beyond countries of the Horn of Africa. The group recommended that infected countries should focus efforts on high-risk and infected areas, by conducting high-quality SIAs no more than four weeks apart.
:: An assessment of outbreak response activities in Ethiopia indicates significant ongoing vaccination coverage gaps in key areas, notably in parts of Somali region of the country. All efforts must be made to fill these vaccination coverage gaps as urgently as possible, which are threatening the regional outbreak response efforts.

WHO: Global Alert and Response (GAR) – Human infection with avian influenza A(H7N9) virus – update 14 February 2014

WHO: Global Alert and Response (GAR) – Disease Outbreak News
http://www.who.int/csr/don/2013_03_12/en/index.html
:: Human infection with avian influenza A(H7N9) virus – update 14 February 2014
The National Health and Family Planning Commission (NHFPC) of China and the Centre for Health Protection (CHP), Hong Kong, SAR, China has notified WHO of a total of eight additional laboratory-confirmed cases of human infection with avian influenza A(H7N9) virus, including one death…So far, there is no evidence of sustained human-to-human transmission….

While the recent report of avian influenza A(H7N9) virus detection in live poultry exported from mainland China to Hong Kong SAR shows the potential for the virus to spread through movement of live poultry, at this time there is no indication that international spread of avian influenza A(H7N9) has occurred. However as the virus infection does not cause signs of disease in poultry, continued surveillance is needed.

Should human cases from affected areas travel internationally, their infection may be detected in another country during or after arrival. If this were to occur, community level spread is unlikely as the virus does not have the ability to transmit easily among human. Until the virus adapts itself for efficient human-to-human transmission, the risk of ongoing international spread of H7N9 virus by travellers is low. The overall risk assessment has not changed.

Further sporadic human cases of avian influenza A(H7N9) infection are expected in affected and possibly neighbouring areas, especially given expected increases in the trade and transport of poultry associated with the Lunar New Year…

:: Human infection with avian influenza A(H7N9) virus – update 11 February 2014
:: Human infection with avian influenza A(H7N9) virus – update 10 February 2014

[Editor’s Note: See Journal Watch below for “Possible pandemic threat from new reassortment of influenza A(H7N9) virus in China” Eurosurveillance, Volume 19, Issue 6, 13 February 2014, http://www.eurosurveillance.org/Public/Articles/Archives.aspx?PublicationId=11678 ]

Commentary: Science for the Poor – Making Vaccines to Combat Poverty

Commentary: Science for the Poor – Making Vaccines to Combat Poverty
Peter Hotez, M.D, Ph.D.
The Huffington Post | 11 February 2014

Is it possible to vaccinate against poverty?

According to the World Bank, an estimated 2.4 billion people live on less than $2 per day, while 1.2 billion live on less than $1.25 per day — a group often referred to as “the bottom billion”. We now know that almost all of the bottom billion and many of those living on less than $2 per day remain trapped in poverty because they are chronically debilitated by a group of afflictions known as the neglected tropical diseases, or ‘NTDs’.

NTDs are long-lasting parasitic and related infections such as ascariasis, trichuriasis, hookworm, schistosomiasis, lymphatic filariasis, onchocerciasis, trachoma, Chagas disease, and leishmaniasis. The major point is that these NTDs can actually cause poverty either because they make people too sick to go to work and limit agricultural productivity, or because they strike children at vulnerable times, thereby stunting their physical and intellectual development.    NTDs also disproportionately affect pregnant women, making them ill and causing them to produce low birth weight or premature infants.

Beyond their staggering public health impact, the economic losses from NTDs are also impressive: our studies with collaborators at Johns Hopkins University show that Chagas disease results in more than $7 billion lost annually, mostly in the Western Hemisphere. There are similar data available for many other NTDs.

Remember, the NTDs are not rare conditions — virtually every single person living in extreme poverty is infected with at least one of these conditions.

Science can offer a lot to prevent these infections, thereby making poor people well enough to   go back to work, children healthy and intellectually vibrant, and improving pregnancy outcomes. One approach now underway is annual mass treatment with a package of essential medicines that targets several NTDs at once, and costs only 50 cents per person. Although not a true vaccine, the World Health Organization uses the term “preventive chemotherapy” to describe this approach because when used over a period of time, together with other supportive measures, it is actually leading to the elimination of lymphatic filariasis and trachoma, and in some cases even river blindness in dozens of impoverished countries. In collaboration with several international organizations we organized a Global Network for NTDs that is raising awareness about the opportunity for these low-cost preventive chemotherapy approaches.

For other NTDs, however, we need new technologies. In 2011 the Sabin Vaccine Institute allied with Texas Children’s Hospital and Baylor College of Medicine to expand its development portfolio of new and novel vaccines to combat NTDs. The result is the expansion of a unique non-profit product development partnership that is located in Houston’s Texas Medical Center — a medical city of 100,000 people — to transition discoveries from the bench to the clinic and produce the next generation ‘antipoverty vaccines’, i.e. vaccines that would not only improve health but simultaneously also lift people out of poverty. For example, hookworm infection affects more than 400 million people in Africa, Asia, and the Americas, where it is a leading cause of anemia and childhood malnutrition, and has been shown to reduce future wage earnings. Our product development partnership, through activities led by Dr. Maria Elena Bottazzi, has developed, transitioned, and produced a prototype hookworm vaccine undergoing clinical trials in Brazil, and will soon undergo additional testing in Gabon through a so-called HOOKVAC consortium of European and African partners. We are also working to evaluate and modify the vaccine so it targets additional parasitic infections such as ascariasis and trichuriasis.
Finally, a new schistosomiasis vaccine is under development and will soon begin clinical trials.

Nor is poverty exclusive to developing countries or failed nations. Today, almost two million families in the United States live on less than $2 per day and poverty is rampant in southern states such as Texas and others along the Gulf Coast. We found that NTDs are also widespread among these impoverished Americans. For example 300,000 people in the United States suffer from Chagas disease, a cause of heart disease transmitted by kissing bugs — our group, which includes a consortium of Mexican institutions, is now working to develop one of the first Chagas disease vaccines for clinical trials.

Dr. Albert Sabin, whose name and legacy our Institute honors once said, “A scientist who is a human being cannot rest while knowledge which might reduce suffering rests on the shelf.” Our Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development is one of six major international product development partnerships currently pioneering vaccine development in the non-profit sector. Together we are making the vaccines for diseases that affect millions if not billions but only those living in extreme poverty.

Almost thirty years ago I graduated from New York’s Rockefeller University, whose motto is Scientia pro bono humani generis – science for the benefit of humanity. Developing a new generation of antipoverty vaccines is a true expression of that concept.

Peter Hotez, M.D., Ph.D. is president of the Sabin Vaccine Institute and the founding dean of the National School of Tropical Medicine at Baylor College of Medicine, where he is also Professor of Pediatrics and Texas Children’s Hospital Endowed Chair of Tropical Pediatrics. Prof. Hotez is also the Fellow on Disease and Poverty at the James A. Baker Institute for Public Policy at Rice University. He is the author of Forgotten People, Forgotten Diseases (ASM Press).

President’s Cancer Panel: Accelerating HPV Vaccine Uptake – Urgency for Action to Prevent Cancer

Report: Accelerating HPV Vaccine Uptake – Urgency for Action to Prevent Cancer
[U.S.] President’s Cancer Panel (PCP):  February 2014
http://deainfo.nci.nih.gov/advisory/pcp/annualReports/HPV/index.htm#sthash.LfsA4o48.dpbs

Overview
Human papillomaviruses (HPV) cause most cases of cervical cancer and large proportions of vaginal, vulvar, anal, penile, and oropharyngeal cancers. HPV also causes genital warts and recurrent respiratory papillomatosis. HPV vaccines could dramatically reduce the incidence of HPV-associated cancers and other conditions among both females and males, but uptake of the vaccines has fallen short of target levels. The President’s Cancer Panel finds underuse of HPV vaccines a serious but correctable threat to progress against cancer. In this report, the Panel presents four goals to increase HPV vaccine uptake: three of these focus on the United States and the fourth addresses ways the United States can help to increase global uptake of the vaccines. Several high-priority research questions related to HPV and HPV vaccines also are identified .

Excerpts from Executive Summary
PART 2: URGENCY FOR ACTION
HPV vaccine uptake has not kept pace with that of other adolescent vaccines and has stalled in the past few years. In 2012, only about one-third of 13- to 17-year-old girls received all three recommended doses. These levels fall considerably short of the U.S. Department of Health and Human Services Healthy People 2020 goal of having 80 percent of 13- to 15-year-old girls fully vaccinated against HPV. Immunization rates for U.S. boys are even lower than for girls. Less than 7 percent of boys ages 13 to 17 completed the series in 2012. This low rate is in large part because the ACIP recommendation for routine vaccination of boys was not made until 2011. However, it is even lower than what was observed for girls in 2007—the first year following the recommendation for females—suggesting that concerted efforts are needed to promote HPV vaccination of males.

The Centers for Disease Control and Prevention (CDC) estimates that increasing HPV vaccination rates from current levels to 80 percent would prevent an additional 53,000 future cervical cancer cases in the United States among girls who now are 12 years old or younger over the course of their lifetimes. Thousands of cases of other HPV-associated cancers in the U.S. also likely would be prevented within the same timeframe. A growing proportion of these cancers—most notably, oropharyngeal cancers—will occur in males, who currently are vaccinated at very low rates.

The President’s Cancer Panel finds underuse of HPV vaccines a serious but correctable threat to progress against cancer. Organized, mutually reinforcing efforts could have synergistic impact on HPV vaccine uptake. The Panel presents four goals to increase HPV vaccine uptake; three goals focus on increasing uptake in the United States (Part 3), and the fourth addresses ways the United States can help increase global uptake of the vaccines (Part 4). Several high-priority research areas also are identified (Part 5). All recommendations and some of the stakeholders responsible for implementing them are summarized in Appendix B.

The Panel urges all stakeholders—including federal and state governments, healthcare professionals, nongovernment organizations with a focus on public health, and parents, caregivers, adolescents, and other members of the public—to contribute to efforts to achieve this goal and protect millions of men and women around the world from the burden of avoidable cancers and other diseases and conditions in the coming years…

PART 4: INCREASING GLOBAL HPV VACCINATION
The burden of HPV-associated cancers extends beyond the borders of the United States, affecting populations in every country. Patterns of HPV-associated cancers differ by region. Cervical cancer is the most common HPV-associated cancer globally. In less developed regions, the large majority of HPV-attributed cancers are cervical cancers. In the United States and other more developed regions, other sites account for a significant proportion of HPV-associated cancers.

While the prevalence of HPV infections and distribution of HPV types vary by region, research has found consistently that HPV16 and HPV18, the cancer-causing strains HPV vaccines protect against, are responsible for at least two-thirds of cervical cancer cases in populations around the world. This provides a strong indication that HPV vaccines will be effective virtually everywhere.

As with cervical cancer screening programs, HPV vaccination programs have been implemented primarily in high-resource areas. Some of the most successful vaccination programs are in Australia, the United Kingdom, and parts of Canada. The U.S. can learn from successful HPV vaccination programs in these and other countries that in some cases have already led to measurable public health benefits.

Addressing the global burden of HPV-associated cancers requires implementation of HPV vaccination programs in low- and middle-income countries, where the majority of HPV-associated cancer cases occur.

:: GOAL 4: PROMOTE GLOBAL HPV VACCINE UPTAKE
The World Health Organization recommends that HPV vaccines be introduced into national immunization programs where prevention of cervical cancer is a public health priority and vaccine introduction is feasible and sustainable. The Panel recommends that the United States collaborate with global partners to support HPV vaccine uptake and other cancer prevention and control activities worldwide.

Objective 4.1: The United States should continue its collaboration with and support of GAVI to facilitate HPV vaccine introduction and uptake in low-income countries.
Objective 4.2: The United States should continue to support global efforts to develop comprehensive cancer control plans and cancer registries in low- and middle-income countries.

****

     Four U.S.-based national medical associations — the American Academy of Family Physicians (AAFP), the American Academy of Pediatrics (AAP), the American College of Physicians (ACP), and American College of Obstetricians and Gynecologists (ACOG) — together with the Immunization Action Coalition and the CDC “issued a call urging physicians across the U.S. to educate their patients about the human papillomavirus (HPV) vaccine, and to strongly recommend HPV vaccination.” In the “Dear Colleague” letter issued today, medical and public health organizations “emphasize to physicians that strong health provider recommendations are critical to increasing the HPV vaccination rate and preventing HPV-associated cancers. Despite more than seven years of vaccine monitoring showing overwhelming evidence of HPV vaccine safety and effectiveness, vaccination rates are not improving while rates for other adolescent vaccines are…”

Feb. 12, 2014 http://www.prnewswire.com/news-releases/leading-medical-and-public-health-organizations-join-efforts-urging-physicians-to-strongly-recommend-human-papillomavirus-hpv-vaccination-245185081.html

Connecting Health Systems Research Ethics to a Broader Health Equity Agenda

The American Journal of Bioethics
Volume 14, Issue 2, 2014
http://www.tandfonline.com/toc/uajb20/current#.Uv_UyrQt6F9

Connecting Health Systems Research Ethics to a Broader Health Equity Agenda
Bridget Pratta
pages 1-3
DOI: 10.1080/15265161.2014.881213
[No abstract]

Ethical Review of Health Systems Research in Low- and Middle-Income Countries: A Conceptual Exploration
Adnan A. Hydera, Abbas Rattania, Carleigh Krubinera, Abdulgafoor M. Bachania & Nhan T. Tranb
DOI: 10.1080/15265161.2013.868950
pages 28-37
http://www.tandfonline.com/doi/abs/10.1080/15265161.2013.868950#.Uv_VlrQt6F8

Abstract
Given that health systems research (HSR) involves different aims, approaches, and methodologies as compared to more traditional clinical trials, the ethical issues present in HSR may be unique or particularly nuanced. This article outlines eight pertinent ethical issues that are particularly salient in HSR and argues that the ethical review process should be better tailored to ensure more efficient and appropriate oversight of HSR with adequate human protections, especially in low- and middle-income countries. The eight ethical areas we discuss include the nature of intervention, types of research subjects, units of intervention and observation, informed consent, controls and comparisons, risk assessment, inclusion of vulnerable groups, and benefits of research. HSR involving human participants is necessary to ensure health systems strengthening and quality of care and to guide public policy intelligently. Health systems researchers must carefully define their intent and goals and openly clarify the values that may influence the premises and design of protocols. As new types of population-level research activities become more commonplace, it is critical that institutional review board (IRB) and research ethics committee (REC) review processes evolve to evaluate these research protocols in ways that address the nuanced features of these studies.

Vulnerability as a Concept for Health Systems Research
Margaret Meek Lange
pages 41-43

Ethical Review of Health Systems Research in Low- and Middle-Income Countries: Research–Treatment Distinction and Intercultural Issues
Shivam Gupta
pages 44-46

No difference in sexual behavior of adolescent girls following Human Papilloma Virus vaccination: a case study two districts in Uganda; Nakasongola and Luwero

BMC Public Health
(Accessed 15 February 2014)
http://www.biomedcentral.com/bmcpublichealth/content

Research article  
No difference in sexual behavior of adolescent girls following Human Papilloma Virus vaccination: a case study two districts in Uganda; Nakasongola and Luwero
Judith Caroline Aujo, Sabrina Bakeera-Kitaka, Sarah Kiguli, Florence Mirembe BMC Public Health 2014, 14:155 (12 February 2014)

Abstract (provisional)
Background
Vaccination against Human Papilloma Virus (HPV) before sexual debut has been recommended by WHO as a primary prevention strategy against cervical cancer. In Uganda, vaccination against HPV started as a demonstration project among young girls in Nakasongola; and Ibanda districts. Studies have suggested that vaccination against HPV could result in risky sexual behavior and increase the risk of early sexual debut.

This study was done to compare the sexual behavior of HPV vaccinated and non vaccinated adolescent girls in two neighboring districts in Uganda; and to assess whether HPV vaccination had any influence on sexual behavior of vaccinated adolescent girls.

Methods
This was an unmatched comparative study, which used both qualitative and quantitative study methods. It was carried out among 400 primary school girls aged 12 to 15 years in the districts of Nakasongola (vaccinated) and Luwero (non vaccinated). Quantitative data was collected using a questionnaire while qualitative data was obtained using focus group discussions and key informant interviews. The main outcome measure was the number of sexually active girls in each group.

Results
Of the 400 girls, 8 volunteered information that they were sexually active, 5(2.5%) from Luwero (non vaccinated) and 3 (1.5%) from Nakasongola (vaccinated), but there was no statistically significant difference between the 2 groups. HPV vaccination was not significantly associated with being sexually active.

Conclusion
There was no significant difference in sexual behavior between vaccinated and non vaccinated girls.

Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods

BMC Public Health
(Accessed 15 February 2014)
http://www.biomedcentral.com/bmcpublichealth/content

Research article
Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods
Cheryl L Gibbons, Marie-Josée J Mangen, Dietrich Plass, Arie H Havelaar, Russell John Brooke, Piotr Kramarz, Karen L Peterson, Anke L Stuurman, Alessandro Cassini, Eric M Fèvre and Mirjam EE Kretzschmar
Author Affiliations
BMC Public Health 2014, 14:147  doi:10.1186/1471-2458-14-147
Published: 11 February 2014

Abstract (provisional)
Background
Efficient and reliable surveillance and notification systems are vital for monitoring public health and disease outbreaks. However, most surveillance and notification systems are affected by a degree of underestimation (UE) and therefore uncertainty surrounds the ‘true’ incidence of disease affecting morbidity and mortality rates. Surveillance systems fail to capture cases at two distinct levels of the surveillance pyramid: from the community since not all cases seek healthcare (under-ascertainment), and at the healthcare-level, representing a failure to adequately report symptomatic cases that have sought medical advice (underreporting). There are several methods to estimate the extent of under-ascertainment and underreporting.

Methods
Within the context of the ECDC-funded Burden of Communicable Diseases in Europe (BCoDE)-project, an extensive literature review was conducted to identify studies that estimate ascertainment or reporting rates for salmonellosis and campylobacteriosis in European Union Member States (MS) plus European Free Trade Area (EFTA) countries Iceland, Norway and Switzerland and four other OECD countries (USA, Canada, Australia and Japan). Multiplication factors (MFs), a measure of the magnitude of underestimation, were taken directly from the literature or derived (where the proportion of underestimated, under-ascertained, or underreported cases was known) and compared for the two pathogens.

Results
MFs varied between and within diseases and countries, representing a need to carefully select the most appropriate MFs and methods for calculating them. The most appropriate MFs are often disease-, country-, age-, and sex-specific.

Conclusions
When routine data are used to make decisions on resource allocation or to estimate epidemiological parameters in populations, it becomes important to understand when, where and to what extent these data represent the true picture of disease, and in some instances (such as priority setting) it is necessary to adjust for underestimation. MFs can be used to adjust notification and surveillance data to provide more realistic estimates of incidence.

Possible pandemic threat from new reassortment of influenza A(H7N9) virus in Chin

Eurosurveillance
Volume 19, Issue 6, 13 February 2014
http://www.eurosurveillance.org/Public/Articles/Archives.aspx?PublicationId=11678

Rapid communications
Possible pandemic threat from new reassortment of influenza A(H7N9) virus in China
Z Meng1, R Han2, Y Hu1, Z Yuan1, S Jiang1, X Zhang1,3, J Xu 1,3

Abstract
Avian influenza A(H7N9) virus re-emerged in China in December 2013, after a decrease in the number of new cases during the preceding six months. Reassortment between influenza A(H7N9) and local H9N2 strains has spread from China’s south-east coast to other regions. Three new reassortments of A(H7N9) virus were identified by phylogenetic analysis: between A(H7N9) and Zhejiang-derived strains, Guangdong/Hong Kong-derived strains or Hunan-derived A(H9N2) strains. Our findings suggest there is a possible risk that a pandemic could develop

Health systems performance assessment in low-income countries: learning from international experiences

Globalization and Health
[Accessed 15 February 2014]
http://www.globalizationandhealth.com/

Research
Health systems performance assessment in low-income countries: learning from international experiences
Christine Kirunga Tashobya, Valéria Campos da Silveira, Freddie Ssengooba, Juliet Nabyonga-Orem, Jean Macq and Bart Criel
Author Affiliations
. Globalization and Health 2014, 10:5  doi:10.1186/1744-8603-10-5
Published: 13 February 2014

Abstract (provisional)
Background
The study aimed at developing a set of attributes for a ‘good’ health system performance assessment (HSPA) framework from literature and experiences in different contexts and using the attributes for a structured approach to lesson learning for low-income countries (LICs).

Methods
Literature review to identify relevant attributes for a HSPA framework; attribute validation for LICs in general, and for Uganda in particular, via a high-level Ugandan expert group; and, finally, review of a selection of existing HSPA frameworks using these attributes.

Results
Literature review yielded six key attributes for a HSPA framework: an inclusive development process; its embedding in the health system’s conceptual model; its relation to the prevailing policy and organizational set-up and societal context; the presence of a concrete purpose, constitutive dimensions and indicators; an adequate institutional set-up; and, its capacity to provide mechanisms for eliciting change in the health system. The expert group contextualized these attributes and added one on the adaptability of the framework.

Lessons learnt from the review of a selection of HSPA frameworks using the attributes include: it is possible and beneficial to involve a range of stakeholders during the process of development of a framework; it is important to make HSPA frameworks explicit; policy context can be effectively reflected in the framework; there are marked differences between the structure and content of frameworks in high-income countries, and low- and middle-income countries; champions can contribute to put HSPA high on the agenda; and mechanisms for eliciting change in the health system should be developed alongside the framework.

Conclusion
It is possible for LICs to learn from literature and the experience of HSPA in other contexts, including HICs. In this study a structured approach to lesson learning included the development of a list of attributes for a ‘good’ HSPA framework. The attributes thus derived can be utilized by LICs like Uganda seeking to develop/adjust their HSPA frameworks as guidelines or a check list, while taking due consideration of the specific context. The review of frameworks from varied contexts, highlighted varied experiences which provide lessons for LICs.

Association of Varying Number of Doses of Quadrivalent Human Papillomavirus Vaccine With Incidence of Condyloma

JAMA   
February 12, 2014, Vol 311, No. 6
http://jama.jamanetwork.com/issue.aspx

Association of Varying Number of Doses of Quadrivalent Human Papillomavirus Vaccine With Incidence of Condyloma
Eva Herweijer, MSc1; Amy Leval, PhD2,3; Alexander Ploner, PhD1; Sandra Eloranta, PhD1; Julia Fridman Simard, ScD4; Joakim Dillner, MD1; Eva Netterlid, PhD5,6,7; Pär Sparén, PhD1; Lisen Arnheim-Dahlström, PhD1
Author Affiliations
JAMA. 2014;311(6):597-603. doi:10.1001/jama.2014.95.
http://jama.jamanetwork.com/article.aspx?articleid=1829685

ABSTRACT
Importance
Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.

Objective
To examine the association between quadrivalent HPV vaccination and first occurrence of condyloma in relation to vaccine dose in a population-based setting.

Design, Setting, and Participants
An open cohort of all females aged 10 to 24 years living in Sweden (n = 1 045 165) was followed up between 2006 and 2010 for HPV vaccination and first occurrence of condyloma using the Swedish nationwide population-based health data registers.

Main Outcomes and Measures
Incidence rate ratios (IRRs) and incidence rate differences (IRDs) of condyloma were estimated using Poisson regression with vaccine dose as a time-dependent exposure, adjusting for attained age and parental education, and stratified on age at first vaccination. To account for prevalent infections, models included a buffer period of delayed case counting.

Results
A total of 20 383 incident cases of condyloma were identified during follow-up, including 322 cases after receipt of at least 1 dose of the vaccine. For individuals aged 10 to 16 years at first vaccination, receipt of 3 doses was associated with an IRR of 0.18 (95% CI, 0.15-0.22) for condyloma, whereas receipt of 2 doses was associated with an IRR of 0.29 (95% CI, 0.21-0.40). One dose was associated with an IRR of 0.31 (95% CI, 0.20-0.49), which corresponds to an IRD of 384 cases (95% CI, 305-464) per 100 000 person-years, compared with no vaccination. The corresponding IRDs for 2 doses were 400 cases (95% CI, 346-454) and for 3 doses, 459 cases (95% CI, 437-482). The number of prevented cases between 3 and 2 doses was 59 (95% CI, 2-117) per 100 000 person-years.

Conclusions and Relevance
Although maximum reduction in condyloma risk was seen after receipt of 3 doses of quadrivalent HPV vaccine, receipt of 2 vaccine doses was also associated with a considerable reduction in condyloma risk. The implications of these findings for the relationship between number of vaccine doses and cervical cancer risk require further investigation.

Human papillomavirus (HPV) types 16 and 18, two HPV types included in the prophylactic HPV vaccines, are implicated in multiple cancer outcomes, including cervical cancer.1,2 The quadrivalent HPV vaccine also protects against HPV types 6 and 11, which cause about 90% of condylomas, also referred to as genital warts.3 Condyloma is the first HPV-related disease end point that can be measured after quadrivalent HPV vaccination because of its short incubation time of between 1 and 6 months.4– 6

Between 2007 and 2011, Sweden had a partially subsidized, opportunistic HPV vaccination program for girls aged 13 to 17 years. Vaccine coverage within this target group was about 25% in 2010.7 Ninety-nine percent of girls vaccinated received the quadrivalent vaccine. In 2012, a school-based vaccination program was launched for girls aged 10 to 12 years, with a catch-up program for girls aged 13 to 18 years, all free of charge.

Both the bivalent and quadrivalent vaccines currently have a 3-dose schedule, which is associated with increased cost and other program feasibility issues.8,9 Dose efficacy has been widely discussed as a fundamental factor in decisions regarding vaccination strategies.8,10,11     The overall protective effects of HPV vaccination programs and requisite efforts appropriate for ensuring complete 3-dose vaccinations are unclear. Small clinical trials have reported measures of vaccine efficacy with less than 3 doses.8,12,13

In contrast to vaccine efficacy trials, population-based studies can examine reduction in disease end points and are more likely to reflect the vaccinated population.14,15 Population-based studies measuring HPV-related diseases provide essential complementary information to studies of vaccine dose efficacy, which primarily assess nondisease end points such as immune response or are designed so that efficacy comparisons cannot be made between multiple dose levels. Registry data in Sweden include unique information on vaccination dose dates for the entire population. The aim of this study was to assess the association between quadrivalent HPV vaccination and condyloma per vaccine dose among young females in a population-based setting.

Legislative Challenges to School Immunization Mandates, 2009-2012 [U.S.]

JAMA   
February 12, 2014, Vol 311, No. 6
http://jama.jamanetwork.com/issue.aspx

Legislative Challenges to School Immunization Mandates, 2009-2012
Saad B. Omer, PhD1; Diane Peterson, BS2; Eileen A. Curran, MPH1; Alan Hinman, MD3; Walter A. Orenstein, MD4
Author Affiliations
JAMA. 2014;311(6):620-621. doi:10.1001/jama.2013.282869.

School immunization mandates, implemented through state-level legislation, have played an important role in maintaining high immunization coverage in the United States. Immunization mandates permit exemptions that vary from state to state in terms of type of exemption (eg, religious, personal belief, medical), and administrative ease of obtaining these exemptions. Certain types of exemptions (especially personal belief exemptions) and the ease of obtaining them are predictive of high rates of vaccine exemptions and increased disease risk among exemptors themselves and in the communities in which they reside.1,2

Early Acquisition of Anogenital Human Papillomavirus Among Teenage Men Who Have Sex With Men

Journal of Infectious Diseases
Volume 209 Issue 5 March 1, 2014
http://jid.oxfordjournals.org/content/current

Young Gay Men and the Quadrivalent Human Papillomavirus Vaccine—Much to Gain (and Lose)
Ross D. Cranston
Department of Medicine, University of Pittsburgh, Pennsylvania
http://jid.oxfordjournals.org/content/209/5/635.extract
Extract
Human papillomavirus (HPV) is the world’s most common viral sexually transmitted infection [1, 2]. Approximately 40 HPV types infect anogenital squamous epithelium and can be broadly divided into low-risk (eg, HPV 6, 11) and high-risk (eg, HPV 16, 18) phenotypes based on their historical association with cervical cancer. This relationship also holds true for other anogenital (anal, vulvar, vaginal) and oropharyngeal malignancies. Although most HPV infections are asymptomatic, when symptoms do occur, they often reflect the presence of warts, dysplasia, or frank malignancy.

Anogenital HPV infection is mostly transient in both sexes, with persistent high-risk HPV infection associated with the development of squamous-cell cancers [3, 4]. HPV prevalence data vary by gender, with men being more likely to have higher-level detection over a wider age range than women, whose prevalence decreases from a peak in their early 20s [3, 5] However, it is men who have sex with men (MSM) who have the highest rates of anogenital HPV infection and also HPV-associated malignancy, particularly HPV 16–associated anal cancer [6, 7].

HPV vaccination has been shown to be safe and effective in preventing the acquisition of anogenital HPV infection and the development of dysplasia [8–10]. The challenge ahead is to ensure that vaccinations are available to those at risk in a manner that optimizes their efficacy.    There are 2 licensed HPV vaccines: a bivalent vaccine directed against HPV 16 and 18 (Cervarix, GlaxoSmithKline, London, UK) licensed for females aged 9–25 years, and a quadrivalent HPV vaccine (qHPV) directed against HPV 6, 11, 16, and 18 (Gardasil, Merck, Whitehouse Station, NJ) licensed for females and males ages 9–26 years. Both vaccines’ indications include prevention of…

Early Acquisition of Anogenital Human Papillomavirus Among Teenage Men Who Have Sex With Men
Huachun Zou1, Sepehr N. Tabrizi2,3,4, Andrew E. Grulich5, Suzanne M. Garland2,3,4, Jane S. Hocking6, Catriona S. Bradshaw1,7,8, Andrea Morrow7, Garrett Prestage5,9, Alyssa M. Cornall3,4, Christopher K. Fairley1,7,9,a and Marcus Y. Chen1,7,9,a
Author Affiliations
1School of Population and Global Health, University of Melbourne, Melbourne, Australia
2Department of Obstetrics and Gynaecology, University of Melbourne
3Department of Microbiology and Infectious Diseases, Royal Women’s Hospital, Melbourne, Australia
4Murdoch Children’s Research Institute, Melbourne, Australia
5Kirby Institute, University of New South Wales, Sydney, Melbourne, Australia
6Centre for Women’s Health, Gender and Society, University of Melbourne, Melbourne, Australia
7Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia
8Central Clinical School, Monash University, Melbourne, Australia
9Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne, Australia
http://jid.oxfordjournals.org/content/209/5/642.abstract

Abstract
Background. Anogenital human papillomavirus (HPV) is common among men who have sex with men (MSM) and causes anal cancer. This study examined the determinants of initial anogenital HPV infection among teenage MSM.

Methods. Two hundred MSM aged 16 to 20 years were recruited via community and other sources. Men were tested for HPV DNA from the anus and penis.

Results. The proportion of men with anal HPV of any type increased from 10.0% in men reporting no prior receptive anal sex to 47.3% in men reporting ≥4 receptive anal sex partners (P < .001).A similar pattern was also seen with HPV type 16 (P = .044). The proportion of men with penile HPV increased from 3.7% in men reporting no prior insertive anal sex to 14.8% in men reporting ≥4 insertive anal sex partners (P = .014). Overall, 39.0% (95% confidence interval (CI), 32.2%−46.1%) of men had at least 1 HPV type: 23.0% (95% CI, 17.4%−29.5%) had a vaccine-preventable type (6, 11, 16 or 18).

Conclusions. Early and high per partner transmission of HPV occurred between men soon after their first sexual experiences. HPV vaccination needs to commence early for maximal prevention of HPV among MSM.

Lancet Editorial: Protecting children in conflict

The Lancet  
Feb 15, 2014  Volume 383  Number 9917  p575 – 668  e12 – 14
http://www.thelancet.com/journals/lancet/issue/current

Editorial
Protecting children in conflict
The Lancet

Preview |
The UN Convention on the Rights of the Child states that children have rights to protection, health, education, and fair treatment. For the children killed, tortured, raped, and abused in conflicts, these rights are far beyond reach.

Last week, a report of the UN Secretary-General on the situation of children and armed conflict in Syria detailed grave violations against children, committed by all parties. More than 10 000 children are estimated to have been killed since March, 2011, many more injured, and countless psychologically affected. The document contains reports of the imprisonment, torture, and murder of children, and their exposure to unthinkable cruelties. Sexual violence is used to harm, humiliate, and intimidate young victims and those forced to witness. Children have been recruited into warfare, abducted for ransom, and used as human shields. They have lost families, homes, schools, and health care.

Tragically, similar reports have surfaced from other nations gripped by conflict. Brutality against children in the Central African Republic is said to be at unprecedented levels; children are being beheaded and maimed amid widespread sexual violence, and an estimated 6000 are associated with armed groups. For children who escape conflict, the psychological scars from witnessing horrific events endure. In South Sudan, orphaned and displaced children will struggle to find their emotional needs met in a country battered by decades of civil war, many living in camps where their security and health are threatened. Children born as refugees might not have birth certificates, crucial to ensure they can access their rights.

By committing atrocities to children, fighters destroy their nation’s future. Damage to children’s health, education, and psychological wellbeing will delay a country’s recovery; without decisive action, a generation in every war zone could become the lasting casualties. Better protection of children is paramount. The Syrian Government has legislated greater child protection, but violations threaten to continue while war lasts. During the conflicts and the aftermath, international communities must seek to heal emotional wounds and safeguard children’s rights.

The Lancet Commissions – The political origins of health inequity: prospects for change

The Lancet  
Feb 15, 2014  Volume 383  Number 9917  p575 – 668  e12 – 14
http://www.thelancet.com/journals/lancet/issue/current

Comment
Protecting health: the global challenge for capitalism
Richard Horton a, Selina Lo a
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2962712-9/fulltext

The quest to secure economic growth, after a financial crisis that raised serious questions about capitalism’s ability to protect and sustain the wellbeing of populations in rich and poor countries alike, is the overriding political priority for many governments today. And those prospects for growth seem good. The World Bank reported in January, 2014, that “advanced economies are turning the corner” and that “developing countries [will] regain strength after two weak years”.1 Specifically, global growth is expected to be 3·2% in 2014, rising to 3·5% by 2016. In high-income countries, growth is predicted to be 2·2% in 2014, rising to 2·4% in 2016. And for developing countries, the expectations are little short of spectacular: projected growth of 5·3% in 2014, rising to 5·7% in 2016. By 2015 it is projected that sub-Saharan Africa will host seven of the world’s fastest growing economies. The World Bank concludes that the world is “finally emerging from the global financial crisis”.

This change in economic fortune should be good news for health. It will mean more resources to invest not only in the health sector, but also in related sectors that shape and influence health, such as education and housing. However, there are disparities between regions. The World Bank1 estimates that China can expect growth of 7·7% in 2014. Sub-Saharan Africa’s growth will likely be 6·4%, excluding South Africa. South Asia should come in at 5·7%, with India at 6·2%. But Latin America and the Middle East are expected to deliver dismal 2·9% and 2·8% growth rates, respectively. Meanwhile, some countries will do less well than their neighbours. Pakistan, 3·4% growth. South Africa, 2·7%. Brazil, 2·4%. Egypt, 2·3%. Central and eastern Europe, 2·1%. Iran, 1%. These between-country disparities will be compounded by within-country inequalities. The World Bank has less to say on this issue. But the lack of inclusive growth within a nation—that is, the exclusion of sectors of the population from the overall benefits of economic growth which should include improved health—will deepen inequality in ways that headline gross domestic product figures fail to reveal.

Economic growth alone will not deliver good health to the most vulnerable sectors of society without addressing the intertwined global factors that challenge or destroy healthy lives. Beyond the economy, recent extreme weather events experienced across most parts of the world are tentative (and incompletely understood) signs that the effects of climate change are already with us. The effect that climate has on the agriculture sector and food security, and the likely impact on nutrition and health outcomes, requires further deep evaluation and cooperation between disciplines. The worsening conflict in Syria, and the continued violence in Iraq, Afghanistan, South Sudan, and the Central African Republic, show the frightening ability of violence to damage health and wellbeing, not only directly, but also indirectly through the social chaos violence inevitably causes. Recent episodes of civil strife in Turkey, Thailand, and Brazil prove that despite considerable health gains, the political systems within which those health gains have taken place are fragile and unstable—lessons that all societies need to relearn, no matter how secure they feel today.

These challenges can be addressed only by reaching beyond the health sector. This might seem an obvious notion but its common understanding and application in global policy debate is weak. Decisions made in different political domains rarely have health at the core of their thinking.

One great gap in thinking about the future of health and wellbeing are the arrangements we put in place to organise our international institutions and policies to sustain the fortunes of societies. These arrangements are inherently political, as Ole Petter Ottersen and his colleagues argue in the final report of The Lancet—University of Oslo Commission on Global Governance for Health.2 They are about power. They are about elites. And they are about a rigid consensus among these powerful elites that prevents most attempts to question the norms on which political decisions are made. Yet elites are only as powerful as the systems that support the status quo. And global systems, such as those in trade, investment, or security, should (but do not always) have mechanisms for civil society participation and links with international norms that already exist to protect health.

The Commission addresses seven political domains that shape health and contribute to inequity within populations: finance, intellectual property, trade and investment treaties, food, corporate activity, migration, and armed conflict. It examines the obstacles to effective global governance for health. And finally, it proposes mechanisms to improve the accountability of all those who influence health through these different sectors. Proposals that could better articulate a way in which civil society engages in global policy, together with ideas for how international institutions could be mandated to produce health equity impact assessments, are worthy of consideration and debate.

The Commission includes contributors from 13 countries, including India, Brazil, Thailand, Tanzania, Ghana, Namibia, South Africa, and the occupied Palestinian territory. They have provided an opportunity to pause and reflect on a problem of emerging and serious importance. The era after the Millennium Development Goals is one that will be substantially more complex than today. The link between poverty and sustainability is not simple. Exclusive anti-poverty measures will not solve some of the biggest health threats people face. Solutions will require specific input from different regions, countries, and individuals—and a more critical understanding than has hitherto been displayed by policy makers of the determinants of human survival and wellbeing. Success will demand courage and flexibility to challenge the consensus that so inhibits the changes needed to bring about greater equity. This Commission can, we hope, be a contribution to this need for greater critical understanding and challenge.

We would like to thank all of the Commissioners for their contributions to this project—and especially Professor Ole Petter Ottersen for leading this work—and are grateful for the support of the Commission from the Norwegian Agency for Development Cooperation, the Norwegian Ministry of Foreign Affairs, the Norwegian Ministry of Education and Research, the Board of the University of Oslo, the University of Oslo’s Institute of Health and Society and Centre for Development and the Environment, and the Harvard Global Health Institute.

References
1 The World Bank. Global economic prospects: coping with policy normalization in high-income countries. Washington, DC: The World Bank, 2014.
2 Ottersen OP, Dasgupta J, Blouin C, et al. The political origins of health inequity: prospects for change. Lancet 2014. published online Feb 11. http://dx.doi.org/10.1016/S0140-6736(13)62407-1.

The Lancet Commissions
-University of Oslo Commission on Global Governance for Health
The political origins of health inequity: prospects for change
Ole Petter Ottersen, Jashodhara Dasgupta, Chantal Blouin, Paulo Buss, Virasakdi Chongsuvivatwong, Julio Frenk, Sakiko Fukuda-Parr, Bience P Gawanas, Rita Giacaman, John Gyapong, Jennifer Leaning, Michael Marmot, Desmond McNeill, Gertrude I Mongella, Nkosana Moyo, Sigrun Møgedal, Ayanda Ntsaluba, Gorik Ooms, Espen Bjertness, Ann Louise Lie, Suerie Moon, Sidsel Roalkvam, Kristin I Sandberg, Inger B Scheel
Full Text | PDF

Executive summary
Despite large gains in health over the past few decades, the distribution of health risks worldwide remains extremely and unacceptably uneven. Although the health sector has a crucial role in addressing health inequalities, its efforts often come into conflict with powerful global actors in pursuit of other interests such as protection of national security, safeguarding of sovereignty, or economic goals.

This is the starting point of The Lancet—University of Oslo Commission on Global Governance for Health. With globalisation, health inequity increasingly results from transnational activities that involve actors with different interests and degrees of power: states, transnational corporations, civil society, and others. The decisions, policies, and actions of such actors are, in turn, founded on global social norms. Their actions are not designed to harm health, but can have negative side-effects that create health inequities. The norms, policies, and practices that arise from global political interaction across all sectors that affect health are what we call global political determinants of health.

The Commission argues that global political determinants that unfavourably affect the health of some groups of people relative to others are unfair, and that at least some harms could be avoided by improving how global governance works. There is an urgent need to understand how public health can be better protected and promoted in the realm of global governance, but this issue is a complex and politically sensitive one. Global governance processes involve the distribution of economic, intellectual, normative, and political resources, and to assess their effect on health requires an analysis of power.

This report examines power disparities and dynamics across a range of policy areas that affect health and that require improved global governance: economic crises and austerity measures, knowledge and intellectual property, foreign investment treaties, food security, transnational corporate activity, irregular migration, and violent conflict. The case analyses show that in the contemporary global governance landscape, power asymmetries between actors with conflicting interests shape political determinants of health.

Key messages
:: The unacceptable health inequities within and between countries cannot be addressed within the health sector, by technical measures, or at the national level alone, but require global political solutions

:: Norms, policies, and practices that arise from transnational interaction should be understood as political determinants of health that cause and maintain health inequities

:: Power asymmetry and global social norms limit the range of choice and constrain action on health inequity; these limitations are reinforced by systemic global governance dysfunctions and require vigilance across all policy arenas

:: There should be independent monitoring of progress made in redressing health inequities, and in countering the global political forces that are detrimental to health

:: State and non-state stakeholders across global policy arenas must be better connected for transparent policy dialogue in decision-making processes that affect health

:: Global governance for health must be rooted in commitments to global solidarity and shared responsibility; sustainable and healthy development for all requires a global economic and political system that serves a global community of healthy people on a healthy planet

Quantifying the Decisional Satisfaction to Accept or Reject the Human Papillomavirus (HPV) Vaccine: A Preference for Cervical Cancer Prevention

PLoS One
[Accessed 15 February 2014]
http://www.plosone.org/

Research Article
Quantifying the Decisional Satisfaction to Accept or Reject the Human Papillomavirus (HPV) Vaccine: A Preference for Cervical Cancer Prevention
Diane M. Harper mail, Billy B. Irons, Natalie M. Alexander, Johanna C. Comes, Melissa S. Smith, Melinda A. Heutinck, Sandra M. Handley, Debra A. Ahern
Published: February 14, 2014
DOI: 10.1371/journal.pone.0088493
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0088493

Abstract
Objective
Only a portion of the US population is willing to consider HPV vaccination to date. The primary aim of this study is to determine the decisional satisfaction associated with HPV vaccination.

Study Design
This is a prospective survey conducted at an urban college where women 18–26 years old completed a decisional satisfaction survey about their HPV vaccine experience.

Results
Regardless of the decision to accept or reject HPV vaccination, the decisional satisfaction was very high (mean 5-item score = 21.2 (SD 3.8)). Women without HPV vaccination were decisionally neutral significantly more often than those already vaccinated; 22% were decisionally neutral for the option to accept HPV vaccination at that visit. Cervical cancer prevention was preferred significantly more often than genital wart prevention in all analyses.

Conclusions
Targeting those who are decisionally neutral about HPV vaccination may result in a higher uptake of HPV vaccination.

Essential Medicines Are More Available than Other Medicines around the Globe

PLoS One
[Accessed 15 February 2014]
http://www.plosone.org/

Research Article
Essential Medicines Are More Available than Other Medicines around the Globe
Yaser T. Bazargani, Margaret Ewen, Anthonius de Boer, Hubert G. M. Leufkens, Aukje K. Mantel-Teeuwisse mail
Published: February 12, 2014
DOI: 10.1371/journal.pone.0087576
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0087576

Abstract
Background
The World Health Organization (WHO) promotes the development of national Essential Medicines Lists (EMLs) in order to improve the availability and use of medicines considered essential within health care systems. However, despite over 3 decades of international efforts, studies show an inconsistent pattern in the availability of essential medicines. We evaluated and compared the availability of essential medicines, and medicines not included in national EMLs, at global and regional levels.

Methods
Medicine availability in the public and private sector were calculated based on data obtained from national and provincial facility-based surveys undertaken in 23 countries using the WHO/HAI methodology. The medicines were grouped according to their inclusion (‘essential’) or exclusion (termed ‘non-essential’) in each country’s EML current at the time of the survey. Availability was calculated for originator brands, generics and any product type (originator brands or generics) and compared between the two groups. Results were aggregated by WHO regions, World Bank country income groups, a wealth inequality measure, and therapeutic groups.

Findings
Across all sectors and any product type, the median availability of essential medicines was suboptimal at 61·5% (IQR 20·6%–86·7%) but significantly higher than non-essential medicines at 27·3% (IQR 3·6%–70·0%). The median availability of essential medicines was 40·0% in the public sector and 78·1% in the private sector; compared to 6·6% and 57·1% for non-essential medicines respectively. A reverse trend between national income level categories and the availability of essential medicines was identified in the public sector.

Interpretation
EMLs have influenced the provision of medicines and have resulted in higher availability of essential medicines compared to non-essential medicines particularly in the public sector and in low and lower middle income countries. However, the availability of essential medicines, especially in the public sector does not ensure equitable access.

Mass Vaccination with a New, Less Expensive Oral Cholera Vaccine Using Public Health Infrastructure in India: The Odisha Model

PLoS Neglected Tropical Diseases
January 2014
http://www.plosntds.org/article/browseIssue.action

Mass Vaccination with a New, Less Expensive Oral Cholera Vaccine Using Public Health Infrastructure in India: The Odisha Model
Shantanu K. Kar, Binod Sah mail, Bikash Patnaik, Yang Hee Kim, Anna S. Kerketta, Sunheang Shin, Shyam Bandhu Rath, Mohammad Ali, Vittal Mogasale, Hemant K. Khuntia, Anuj Bhattachan, Young Ae You, Mahesh K. Puri, Thomas F. Wierzba
http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0002629#close

Abstract
Introduction
The substantial morbidity and mortality associated with recent cholera outbreaks in Haiti and Zimbabwe, as well as with cholera endemicity in countries throughout Asia and Africa, make a compelling case for supplementary cholera control measures in addition to existing interventions. Clinical trials conducted in Kolkata, India, have led to World Health Organization (WHO)-prequalification of Shanchol, an oral cholera vaccine (OCV) with a demonstrated 65% efficacy at 5 years post-vaccination. However, before this vaccine is widely used in endemic areas or in areas at risk of outbreaks, as recommended by the WHO, policymakers will require empirical evidence on its implementation and delivery costs in public health programs. The objective of the present report is to describe the organization, vaccine coverage, and delivery costs of mass vaccination with a new, less expensive OCV (Shanchol) using existing public health infrastructure in Odisha, India, as a model.

Methods
All healthy, non-pregnant residents aged 1 year and above residing in selected villages of the Satyabadi block (Puri district, Odisha, India) were invited to participate in a mass vaccination campaign using two doses of OCV. Prior to the campaign, a de jure census, micro-planning for vaccination and social mobilization activities were implemented. Vaccine coverage for each dose was ascertained as a percentage of the censused population. The direct vaccine delivery costs were estimated by reviewing project expenditure records and by interviewing key personnel.

Results
The mass vaccination was conducted during May and June, 2011, in two phases. In each phase, two vaccine doses were given 14 days apart. Sixty-two vaccination booths, staffed by 395 health workers/volunteers, were established in the community. For the censused population, 31,552 persons (61% of the target population) received the first dose and 23,751 (46%) of these completed their second dose, with a drop-out rate of 25% between the two doses. Higher coverage was observed among females and among 6–17 year-olds. Vaccine cost at market price (about US$1.85/dose) was the costliest item. The vaccine delivery cost was $0.49 per dose or $1.13 per fully vaccinated person.

Discussion
This is the first undertaken project to collect empirical evidence on the use of Shanchol within a mass vaccination campaign using existing public health program resources. Our findings suggest that mass vaccination is feasible but requires detailed micro-planning. The vaccine and delivery cost is affordable for resource poor countries. Given that the vaccine is now WHO pre-qualified, evidence from this study should encourage oral cholera vaccine use in countries where cholera remains a public health problem.

Author Summary
Cholera – an acute life-threatening diarrheal illness – continues to disrupt public health in resource poor countries. The devastating outbreaks in Haiti and Zimbabwe – to name just two of many occurrences – calls for the use of available oral cholera vaccines as an additional tool in the arsenal of cholera control measures. An oral cholera vaccine (Shanchol) has been licensed in India since 2009; however, there has only been limited use of this vaccine in government public health programs. A vaccination campaign using 2 doses of Shanchol was conducted in Odisha, India, during May and June, 2011, where 31,552 persons (61% of the target population) received the first dose and 23,751 of them completed their second dose. The vaccine delivery cost was $0.49 per dose. Through our findings and experience, we discuss the organization of the cholera vaccination campaign in Odisha, the challenges met for conducting the campaign and the strategies designed to overcome those challenges, and the delivery costs incurred in the use of this vaccine, the first of its kind, in a public health setting. We believe that evidence from this study is of significant interest and use to policymakers from countries where cholera remains a public health problem.

The economic burden of sixteen measles outbreaks on United States public health departments in 2011

Vaccine
Volume 32, Issue 11, Pages 1227-1322 (5 March 2014)
http://www.sciencedirect.com/science/journal/0264410X/32

The economic burden of sixteen measles outbreaks on United States public health departments in 2011
Original Research Article
Pages 1311-1317
Ismael R. Ortega-Sanchez, Maya Vijayaraghavan, Albert E. Barskey, Gregory S. Wallace

Abstract
Background
Despite vaccination efforts and documentation of elimination of indigenous measles in 2000, the United States (US) experienced a marked increase in imported cases and outbreaks of measles in 2011. Due to the high infectiousness and potential severity of measles, these outbreaks require a vigorous response from public health institutions. The effort and resources required to respond to these outbreaks are likely to impose a significant economic burden on these institutions.

Objective
To estimate the economic burden of measles outbreaks (defined as ≥3 epidemiologically linked cases) on the local and state public health institutions in the US in 2011.

Methods
From the perspective of local and state public health institutions, we estimated personnel time and resources allocated to measles outbreak response in local and state public health departments, and estimated the corresponding costs associated with these outbreaks in the US in 2011. We used cost and resource utilization data from previous studies on measles outbreaks in the US and, relying on outbreak size classification based on a case-day index, we estimated costs incurred by local and state public health institutions.

Results
In 2011, the US experienced 16 outbreaks with 107 confirmed cases. The average duration of an outbreak was 22 days (range: 5–68). The total estimated number of identified contacts to measles cases ranged from 8936 to 17,450, requiring from 42,635 to 83,133 personnel hours. Overall, the total economic burden on local and state public health institutions that dealt with measles outbreaks during 2011 ranged from an estimated $2.7 million to $5.3 million US dollars.

Conclusion
Investigating and responding to measles outbreaks imposes a significant economic burden on local and state health institutions. Such impact is compounded by the duration of the outbreak and the number of potentially susceptible contacts.

Increased measles–mumps–rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England

Vaccine
Volume 32, Issue 10, Pages 1131-1226 (26 February 2014)
http://www.sciencedirect.com/science/journal/0264410X/32/10

Increased measles–mumps–rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England
Original Research Article
Pages 1147-1152
Arnaud Le Menach, Naomi Boxall, Gayatri Amirthalingam, Liz Maddock, Sooria Balasegaram, Miranda Mindlin

Abstract
Background
Following a measles outbreak in a vaccine-rejecting community between April and September 2011 in South-East England, local health agencies implemented a two-pronged measles–mumps–rubella (MMR) immunisation campaign from August to October offered at the local general practice where most cases were registered. The campaign included (a) accelerated vaccination of children earlier than scheduled (1st dose at 6–11 months, or 2nd dose at 18–39 months), (b) catch-up of those aged over 18 months who had had no MMR immunisations or were late for second MMR. We investigated the impact of the outbreak and campaign on the number of MMR doses given.

Materials and methods
In January 2012, we collected information on MMR vaccination for children registered at the practice aged 6 months–16 years on 1 August 2011, through the child health information system. We counted the number of MMR doses administered in 2011 and compared it to 2008–2010 data. We estimated the proportion vaccinated among the children eligible for the accelerated and catch-up campaign.

Results
The local practice administered 257 MMR doses in 2011, a 114% increase on the average for 2008–2010. Among children eligible for earlier MMR vaccination 5/26 (19%) received a first dose, and 34/57 (60%) a second dose. Among children eligible for catch-up, 20/329 (6%) received their first MMR and 39/121 (32%) their second. Of 1538 children, the proportion completely unimmunised for MMR declined by 3 percentage-points after the outbreak.

Discussion
Uptake of MMR vaccination significantly increased during the outbreak following the immunisation campaign. Those amenable to MMR vaccination seem to have benefited from the campaign more than those with no previous vaccinations. Future evaluations should address what made a few parents change their mind and have their children vaccinated for the first time during the outbreak

Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention

Vaccines — Open Access Journal
(Accessed 15 February 2014)
http://www.mdpi.com/journal/vaccines

Review
Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention
by Lucia H. Lee, Xin-Xing Gu and Moon H. Nahm
Vaccines 2014, 2(1), 112-128; doi:10.3390/vaccines2010112 – published online 14 February 2014
Abstract: Seven-valent pneumococcal conjugate vaccine (PCV7) introduction and routine pediatric use has substantially reduced the burden of Streptococcus pneumoniae disease worldwide. However, a significant amount of disease burden, due to serotypes not contained in PCV7, still exists globally. A newly recognized serotype, 6C, was until recently, identified and reported as serotype 6A. This review summarizes the serotype epidemiology of pneumococcal disease pre- and post-introduction of PCV7, available post-marketing surveillance data following the introduction of higher valency pneumococcal vaccines (PCV10, PCV13) and future prospects for the development of new pneumococcal vaccines.